{
 "Fenotipo_No_Especificado": 6204,
 "Side Effect:Drug Toxicity": 195,
 "Efficacy:Overall survival": 150,
 "Side Effect:Neutropenia": 134,
 "Efficacy:Progression-free survival": 111,
 "Side Effect:Drug-induced liver injury": 111,
 "Disease:Drug Toxicity": 91,
 "Side Effect:adverse events": 91,
 "Side Effect:Toxic liver disease": 87,
 "Side Effect:Hemorrhage": 81,
 "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome": 72,
 "Disease:Toxic liver disease": 65,
 "Efficacy:Sustained virological response (SVR)": 65,
 "Side Effect:Leukopenia": 64,
 "Side Effect:Diarrhea": 64,
 "Side Effect:Severe Cutaneous Adverse Reactions": 62,
 "Side Effect:Weight gain": 60,
 "Side Effect:over-anticoagulation": 59,
 "Side Effect:Drug Hypersensitivity": 52,
 "Side Effect:Peripheral Nervous System Diseases": 51,
 "Disease:Severe Cutaneous Adverse Reactions": 49,
 "Side Effect:Thrombocytopenia": 48,
 "Disease:Neutropenia": 47,
 "Efficacy:event-free survival": 44,
 "Disease:Tobacco Use Disorder": 43,
 "Side Effect:Hand-foot syndrome": 43,
 "Efficacy:Recurrence": 37,
 "Other:warfarin dose": 37,
 "Side Effect:Cardiotoxicity": 36,
 "Side Effect:Alcohol abuse": 36,
 "Side Effect:Neurotoxicity Syndromes": 34,
 "Side Effect:Gastrointestinal toxicity": 33,
 "Efficacy:overall survival": 32,
 "Side Effect:Anemia": 32,
 "Side Effect:Hyperbilirubinemia": 31,
 "Side Effect:Mucositis": 31,
 "Side Effect:Myelosuppression": 30,
 "Efficacy:high on-treatment platelet reactivity": 30,
 "Efficacy:remission": 29,
 "Side Effect:statin-related myopathy": 29,
 "Side Effect:toxicity": 28,
 "Disease:Stevens-Johnson Syndrome": 27,
 "Efficacy:non-response": 27,
 "Disease:Death": 27,
 "Disease:Diarrhea": 26,
 "Efficacy:Overall survival, Efficacy:Progression-free survival": 26,
 "Other:Heroin Dependence": 26,
 "Other:Opioid-Related Disorders": 25,
 "Efficacy:progression-free survival (PFS) time": 24,
 "Side Effect:Agranulocytosis": 24,
 "Efficacy:platelet reactivity": 24,
 "Side Effect:Discontinuation": 24,
 "Side Effect:Exanthema": 24,
 "Side Effect:Graft vs Host Disease": 23,
 "Disease:Maculopapular Exanthema": 22,
 "Disease:Anemia": 21,
 "Efficacy:survival": 21,
 "Side Effect:Major Adverse Cardiac Events (MACE)": 21,
 "Side Effect:Nephrotoxicity": 21,
 "Side Effect:Nausea, Side Effect:Vomiting": 21,
 "Disease:Drug Hypersensitivity": 21,
 "Side Effect:Ototoxicity": 20,
 "Side Effect:Opioid-Related Disorders": 20,
 "Efficacy:Pain": 20,
 "PK:plasma concentration": 20,
 "Other:Tobacco Use Disorder": 20,
 "Side Effect:side effects": 19,
 "Disease:Ototoxicity": 19,
 "Disease:Peripheral Nervous System Diseases": 19,
 "Efficacy:time to therapeutic inr": 19,
 "Disease:Alcohol abuse": 19,
 "Efficacy:Recurrence free survival": 19,
 "Side Effect:Nausea": 19,
 "Disease:Weight gain": 18,
 "Efficacy:Transplant rejection": 17,
 "Side Effect:cardiovascular events": 17,
 "Other:Alcohol abuse": 17,
 "Disease:Diabetes Mellitus": 16,
 "Efficacy:response rate": 16,
 "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms": 16,
 "Side Effect:Aspirin-induced asthma": 15,
 "Side Effect:Vomiting": 15,
 "Side Effect:Angioedema": 15,
 "Side Effect:Hypertension": 15,
 "Side Effect:Hypersensitivity": 15,
 "Disease:Heroin Dependence": 15,
 "Disease:Asthma": 15,
 "Side Effect:Osteonecrosis": 14,
 "Side Effect:Elevated liver enzymes": 14,
 "Efficacy:Major Adverse Cardiac Events (MACE)": 14,
 "Side Effect:Leukopenia, Side Effect:Neutropenia": 14,
 "Disease:Myocardial Infarction": 14,
 "Other:COVID-19": 14,
 "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis": 14,
 "Disease:Tardive Dyskinesia": 14,
 "Side Effect:Death": 14,
 "Side Effect:Muscular Diseases": 13,
 "Efficacy:bronchodilator response (FEV1)": 13,
 "Side Effect:bone density": 13,
 "Other:platelet reactivity": 13,
 "Efficacy:time to achieve stable dose": 13,
 "PK:AUC": 13,
 "Efficacy:Treatment failure": 13,
 "Disease:Opioid-Related Disorders": 13,
 "Disease:Malignant Hyperthermia": 13,
 "Efficacy:platelet aggregation": 13,
 "Other:Smoking Cessation": 13,
 "Side Effect:Hypoventilation": 12,
 "Disease:Neurotoxicity Syndromes": 12,
 "Efficacy:response": 12,
 "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia": 12,
 "Side Effect:Postoperative Nausea and Vomiting": 12,
 "Side Effect:Metabolic Syndrome": 12,
 "Side Effect:stent thrombosis": 12,
 "Disease:Breast Neoplasms": 12,
 "PK:dose-adjusted trough concentrations": 12,
 "Efficacy:reduction in blood pressure": 11,
 "Efficacy:event free survival": 11,
 "Disease:Acute coronary syndrome": 11,
 "Disease:Substance-Related Disorders": 11,
 "Efficacy:progression-free survival": 11,
 "Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR)": 10,
 "Side Effect:Hyperprolactinemia": 10,
 "Disease:Leukopenia": 10,
 "Disease:Nausea": 10,
 "Efficacy:Discontinuation": 10,
 "Other:QT interval": 10,
 "Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome": 10,
 "Efficacy:Progression-free survival, Efficacy:Overall survival": 10,
 "Other:opiate withdrawal symptoms": 10,
 "Side Effect:Stevens-Johnson Syndrome": 10,
 "Disease:Drug-induced liver injury": 10,
 "Side Effect:Maculopapular Exanthema": 10,
 "Side Effect:Urticaria": 9,
 "Disease:Thrombocytopenia": 9,
 "Disease:Cough": 9,
 "Disease:Psychotic Disorder": 9,
 "Side Effect:Tardive Dyskinesia": 9,
 "PK:plasma concentrations": 9,
 "Side Effect:Cough": 9,
 "Efficacy:smoking cessation": 9,
 "Efficacy:Elevated diastolic blood pressure": 9,
 "Disease:Thrombotic disease": 9,
 "Disease:Hand-foot syndrome": 9,
 "Side Effect:Somnolence": 9,
 "Efficacy:Death": 9,
 "PK:trough concentrations": 9,
 "Side Effect:Venous Thrombosis": 9,
 "Efficacy:rapid virological response (rvr)": 8,
 "Disease:Coronary Artery Disease": 8,
 "Disease:Colorectal Neoplasms": 8,
 "Disease:Fatigue": 8,
 "Disease:Transplant rejection": 8,
 "Disease:Hypercholesterolemia": 8,
 "Side Effect:Overdose": 8,
 "Side Effect:sexual side-effects": 8,
 "Disease:Cocaine dependence": 8,
 "Efficacy:time in therapeutic range": 8,
 "Other:adenomatous and hyperplastic polyps": 8,
 "PK:tacrolimus concentration to dose ratio (C/D ratio)": 8,
 "Disease:Pain": 8,
 "Efficacy:Disease Progression": 8,
 "Side Effect:Alopecia": 7,
 "Efficacy:Hypercholesterolemia": 7,
 "Side Effect:suicidal ideation": 7,
 "Side Effect:Physiological sexual disorder": 7,
 "Other:Death": 7,
 "Efficacy:drug resistance": 7,
 "Other:mean arterial pressure": 7,
 "Efficacy:opioids response": 7,
 "Efficacy:Pain, Postoperative": 7,
 "Side Effect:ischaemic events": 7,
 "Side Effect:time above therapeutic range": 7,
 "Side Effect:Pneumonitis": 7,
 "Side Effect:cardiotoxicity": 7,
 "Efficacy:progression free survival": 7,
 "Disease:Muscular Diseases": 7,
 "Side Effect:Asthenia": 7,
 "PK:serum concentration": 7,
 "Efficacy:disease free survival": 7,
 "Side Effect:sedation": 6,
 "Efficacy:response rate (RR)": 6,
 "Side Effect:Depression": 6,
 "Efficacy:reduction in total cholesterol": 6,
 "Side Effect:Pancreatitis": 6,
 "Side Effect:Tobacco Use Disorder": 6,
 "Side Effect:Pain": 6,
 "Side Effect:aspirin-intolerant asthma": 6,
 "Side Effect:Bradycardia, Side Effect:Hypotensive disorder": 6,
 "Disease:Rhabdomyolysis": 6,
 "Disease:Agranulocytosis": 6,
 "Disease:Coronary Disease": 6,
 "Side Effect:anxiety": 6,
 "Other:Recurrent pregnancy loss": 6,
 "Side Effect:Treatment interruption": 6,
 "Other:Substance-Related Disorders": 6,
 "Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression": 6,
 "Side Effect:Elevated circulating creatine kinase concentration": 6,
 "Efficacy:Smoking Cessation": 6,
 "Efficacy:platelet aggregation inhibition": 6,
 "PK:DPD activity": 6,
 "Efficacy:overall survival and progression-free survival": 6,
 "Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome": 6,
 "PK:plasma drug levels": 6,
 "Efficacy:inhibition of ADP-induced platelet aggregation": 6,
 "Efficacy:international normalized ratio variability (inr-var)": 5,
 "Other:prolactin": 5,
 "Disease:Lung Neoplasms": 5,
 "PK:concentration/dose ratio": 5,
 "Efficacy:Drug Resistance": 5,
 "Efficacy:time to the first INR within the therapeutic range": 5,
 "Disease:Colonic Neoplasms": 5,
 "Efficacy:Myocardial Infarction, Efficacy:Stroke, Efficacy:Death": 5,
 "Efficacy:resistant hypertension": 5,
 "Side Effect:bleeding events": 5,
 "Disease:Nephrotoxicity": 5,
 "Side Effect:neutropenia": 5,
 "Side Effect:severe myelosuppression": 5,
 "Efficacy:residual platelet reactivity": 5,
 "Side Effect:Venous thromboembolism": 5,
 "Side Effect:Hyperglycemia": 5,
 "Side Effect:Heroin Dependence": 5,
 "Disease:Exanthema": 5,
 "Efficacy:non-response and required higher dose": 5,
 "Efficacy:overall survival (OS) time": 5,
 "Side Effect:adverse cardiovascular events": 5,
 "Other:Gilbert syndrome, Other:Crigler-Najjar Syndrome": 5,
 "PK:median oral clearance of doxepin": 5,
 "Side Effect:Cardiovascular Disease": 5,
 "Efficacy:cytotoxicity": 5,
 "Side Effect:Febrile neutropenia": 5,
 "Other:warfarin dose requirements on day 14": 5,
 "Other:Gastric pH": 5,
 "Efficacy:sedation": 5,
 "Efficacy:Stroke": 5,
 "Efficacy:Decreased glomerular filtration rate": 5,
 "Efficacy:LDL-C response": 5,
 "Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant": 5,
 "Other:Overall survival": 5,
 "Side Effect:Psoriasis": 5,
 "Side Effect:dose delay": 5,
 "PK:baseline LDL cholesterol": 5,
 "Efficacy:LDL-C reduction": 5,
 "Side Effect:Dizziness": 5,
 "Efficacy:relapse": 5,
 "Other:smoking": 5,
 "Side Effect:weight gain": 5,
 "Disease:Myalgia": 5,
 "Side Effect:Bullous Pemphigoid": 5,
 "Side Effect:extrapyramidal symptoms": 5,
 "Disease:Drug Reaction with Eosinophilia and Systemic Symptoms": 5,
 "Side Effect:Infectious disease": 5,
 "Side Effect:dermatologic toxicity": 5,
 "Side Effect:Esophagitis": 4,
 "Efficacy:event-free survival, Efficacy:Overall survival": 4,
 "Efficacy:reduction in mean blood pressure": 4,
 "Side Effect:Hemolytic Anemia": 4,
 "PK:IC50": 4,
 "Disease:Hypertension, Portal": 4,
 "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Stevens-Johnson Syndrome": 4,
 "Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Other:Discontinuation": 4,
 "Side Effect:Anemia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting": 4,
 "Side Effect:adverse reactions": 4,
 "PK:glucuronidation": 4,
 "Efficacy:slower response time": 4,
 "Disease:Major Depressive Disorder": 4,
 "Side Effect:Lymphopenia": 4,
 "Efficacy:decreased warfarin dose and increased risk of over-anticoagulation": 4,
 "Side Effect:Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome": 4,
 "Other:Hyperuricemia": 4,
 "PK:plasma level": 4,
 "Side Effect:Diabetes Mellitus": 4,
 "Efficacy:reduction in whole day ambulatory blood pressure": 4,
 "Disease:Aspirin-induced asthma": 4,
 "Efficacy:resistance": 4,
 "Disease:Anemia, Disease:Leukopenia, Disease:Neutropenia, Disease:Thrombocytopenia": 4,
 "Side Effect:sexual dysfunction": 4,
 "Disease:Rheumatoid arthritis": 4,
 "PK:pravastatin plasma concentrations (AUC) and Cmax": 4,
 "Disease:Parkinson Disease": 4,
 "Disease:Recurrence": 4,
 "Other:Pain": 4,
 "Side Effect:intolerance": 4,
 "Side Effect:Hypertriglyceridemia": 4,
 "Side Effect:Central Nervous System Disorder": 4,
 "Efficacy:Cryoglobulinemia": 4,
 "Side Effect:Nevirapine-induced rash": 4,
 "PK:trough concentration": 4,
 "Side Effect:Pneumonia": 4,
 "Side Effect:GI toxicity": 4,
 "Side Effect:leukopenia": 4,
 "Disease:Hypertriglyceridemia": 4,
 "Efficacy:post-HbA1c levels": 4,
 "Side Effect:Respiratory Insufficiency": 4,
 "Disease:Hyperbilirubinemia": 4,
 "Other:warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy": 4,
 "Efficacy:complete early virological response": 4,
 "Side Effect:Drug Toxicity, Side Effect:Eye Diseases": 4,
 "Side Effect:major adverse cardiac and cerebrovascular events": 4,
 "Side Effect:opioid withdrawal symptoms": 4,
 "Side Effect:Osteonecrosis of the jaw": 4,
 "Other:Alcohol abuse, Other:Cocaine dependence, Other:Opioid-Related Disorders": 4,
 "Other:addiction": 4,
 "Other:requiring postoperative intervention": 4,
 "Efficacy:recurrence": 4,
 "Side Effect:Hyperlipidemias": 4,
 "Efficacy:efficacy": 4,
 "Side Effect:Acquired Long QT Syndrome (aLQTS)": 4,
 "Other:aspirin-intolerant asthma": 4,
 "Efficacy:Acute cellular rejection": 3,
 "Efficacy:Graft vs Host Disease": 3,
 "Side Effect:Pancytopenia, Side Effect:Thrombocytopenia": 3,
 "Efficacy:bone density": 3,
 "Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions": 3,
 "Efficacy:Iron Overload": 3,
 "Side Effect:nausea/vomiting": 3,
 "Side Effect:Amenorrhea": 3,
 "Side Effect:major but not minor hemorrhage": 3,
 "PK:AUC simvastatin acid": 3,
 "Efficacy:diuretic unresponsiveness": 3,
 "Side Effect:obsessive-compulsive symptoms": 3,
 "Efficacy:Myocardial Infarction, Efficacy:Stroke": 3,
 "Disease:Chronic Obstructive Pulmonary Disease": 3,
 "Other:smoking cessation": 3,
 "Side Effect:amiodarone-induced ventricular arrhythmia and QT prolongation": 3,
 "Efficacy:nonresponse to methadone maintenance treatment": 3,
 "Efficacy:vol% end-tidal sevoflurane concentration": 3,
 "Side Effect:Blood Coagulation Disorders": 3,
 "Side Effect:Hematologic Disorder": 3,
 "Efficacy:event-free survival, Efficacy:Recurrence free survival": 3,
 "Side Effect:Dose reduction": 3,
 "Side Effect:kidney tubular dysfunction": 3,
 "Side Effect:adverse clinical events": 3,
 "Disease:Sickle cell pain crisis": 3,
 "Efficacy:smoking abstinence within slow nicotine metabolizers": 3,
 "Efficacy:antiplatelet response and reduced clopidogrel active metabolite formation": 3,
 "Other:Discontinuation": 3,
 "Other:Cocaine dependence": 3,
 "Efficacy:time to progression": 3,
 "PK:plasma Cmin values": 3,
 "Side Effect:Myalgia": 3,
 "Side Effect:Hemorrhage, Side Effect:Stroke": 3,
 "Side Effect:adverse effects": 3,
 "Side Effect:Anaphylaxis": 3,
 "Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms": 3,
 "Side Effect:CNS depression in breast-feeding infants": 3,
 "Efficacy:protection from drug resistance": 3,
 "PK:metabolic ratio": 3,
 "PK:plasma nortriptyline": 3,
 "Disease:Cardiotoxicity": 3,
 "Efficacy:cardiac events": 3,
 "Side Effect:systolic blood pressure and increased risk of developing grade 3 hypertension": 3,
 "Side Effect:Sudden cardiac death": 3,
 "Disease:event-free survival": 3,
 "Side Effect:a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients": 3,
 "Other:plasma level of high-sensitivity C-reactive protein": 3,
 "PK:clearance": 3,
 "Side Effect:Hot Flashes": 3,
 "Efficacy:drug-resistant phenotype": 3,
 "Disease:Hypertension": 3,
 "Disease:Postoperative Nausea and Vomiting": 3,
 "Disease:Osteonecrosis": 3,
 "Side Effect:Constipation": 3,
 "Disease:Stroke": 3,
 "Disease:Insulin Resistance": 3,
 "Efficacy:high post-treatment platelet reactivity": 3,
 "Disease:Infectious disease": 3,
 "Side Effect:Transplant rejection": 3,
 "Side Effect:hematologic toxicity": 3,
 "Efficacy:Nausea, Efficacy:Vomiting": 3,
 "Side Effect:Drug Toxicity, Side Effect:Treatment modification": 3,
 "PK:plasma exposure": 3,
 "Efficacy:Disease activity score 28 in rheumatoid arthritis": 3,
 "Disease:Cardiomyopathies": 3,
 "Other:Asthma": 3,
 "Disease:Progression-free survival": 3,
 "Efficacy:residual on-clopidogrel platelet reactivity": 3,
 "Other:heart rate": 3,
 "PK:mean logarithm escitalopram concentration": 3,
 "Other:intragastric pH": 3,
 "Side Effect:Gastrointestinal Hemorrhage": 3,
 "Efficacy:dying": 3,
 "Disease:Depression": 3,
 "PK:bioavailability": 3,
 "Disease:Kidney Disorder": 3,
 "PK:pravastatin plasma concentrations (AUC)": 3,
 "Side Effect:Obesity": 3,
 "Side Effect:neutropenia grade 3-4": 3,
 "Disease:Liver Failure, Acute": 3,
 "Efficacy:death": 3,
 "Disease:Adenoma": 3,
 "Side Effect:over anti-coagulation": 3,
 "Other:Progression-free survival": 3,
 "PK:venlafaxine levels": 3,
 "Other:time to tumor recurrence (TTR)": 3,
 "Side Effect:periorbital edema": 3,
 "PK:dose-corrected plasma concentrations": 3,
 "Other:reductions in glutathione levels": 3,
 "PK:doxorubicinol AUC": 3,
 "Disease:Heart Failure": 3,
 "Side Effect:anemia": 3,
 "PK:paroxetine plasma concentration": 3,
 "PK:paroxetine plasma concentrations increased during the course of pregnancy": 3,
 "Disease:Suicide": 3,
 "Side Effect:Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions": 3,
 "Other:abstinence": 3,
 "Other:Sickle cell pain crisis": 3,
 "Side Effect:Toxic Epidermal Necrolysis": 3,
 "Efficacy:Leukocytosis": 3,
 "Other:habitual consumption": 3,
 "Side Effect:Hepatitis": 3,
 "PK:mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication": 3,
 "Side Effect:hypersensitivity": 3,
 "Efficacy:ADP-induced platelet aggregation (PA)": 3,
 "PK:plasma efavirenz levels": 3,
 "Side Effect:Fatigue": 3,
 "Side Effect:Nephrolithiasis": 3,
 "Side Effect:adverse drug reactions": 3,
 "Efficacy:metabolism and decreased response to tramadol": 3,
 "Efficacy:response to metformin": 3,
 "Disease:Diabetes, Gestational": 3,
 "Other:better survival outcome": 3,
 "Disease:Myelosuppression": 3,
 "Efficacy:cardiovascular death, myocardial infarction, or stroke": 3,
 "Efficacy:resistant relapse": 3,
 "Efficacy:inhibition of platelet aggregation and poor-responder status": 3,
 "PK:exposure to clopidogrel active metabolite": 3,
 "Efficacy:delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5": 3,
 "Disease:Central Nervous System Disorder": 3,
 "Side Effect:Pruritus": 3,
 "PK:imatinib clearance": 3,
 "Side Effect:Thromboembolism": 3,
 "Other:plasma level": 3,
 "PK:metformin secretory clearance": 3,
 "Side Effect:hepatotoxicity": 3,
 "Efficacy:on-treatment platelet reactivity": 3,
 "Disease:Hepatitis": 3,
 "Side Effect:mucositis": 3,
 "Side Effect:gastrointestinal side effects": 3,
 "Side Effect:Nausea, Side Effect:Vomiting, Side Effect:Diarrhea, Side Effect:Gastrointestinal toxicity": 2,
 "Efficacy:Elevated systolic blood pressure": 2,
 "Efficacy:emerging viral drug resistance": 2,
 "Side Effect:plasma total homocysteine concentrations": 2,
 "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death": 2,
 "Side Effect:Neutropenia, Side Effect:Leukopenia": 2,
 "Side Effect:Intracranial Hemorrhages": 2,
 "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression": 2,
 "Efficacy:a decrease in visual analog scale >30mm within 6 hours": 2,
 "Side Effect:Dyslipidaemia": 2,
 "Efficacy:reduction of LDL cholesterol": 2,
 "Efficacy:Event-Free Survival": 2,
 "Efficacy:pain relief": 2,
 "Side Effect:Hypercholesterolemia": 2,
 "Side Effect:Acute cellular rejection": 2,
 "Side Effect:bleeding": 2,
 "Disease:Hemorrhage": 2,
 "PK:citalopram oral clearances of citalopram": 2,
 "PK:serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios": 2,
 "Efficacy:Overall survival, Efficacy:Recurrence free survival": 2,
 "Other:atopy in patients with aspirin-intolerant chronic urticaria": 2,
 "Side Effect:Discontinuation, Side Effect:Myelosuppression": 2,
 "Disease:Dizziness": 2,
 "Efficacy:Myocardial Infarction, Efficacy:Myocardial Ischemia, Efficacy:Stroke": 2,
 "PK:plasma concentrations of O-desmethyltramadol": 2,
 "Side Effect:renal proximal tubulopathy": 2,
 "Side Effect:Hemorrhage, Side Effect:adverse events": 2,
 "Side Effect:Thrombotic disease": 2,
 "Side Effect:Cognitive disorder": 2,
 "Side Effect:Nausea, Side Effect:Headache, Side Effect:Insomnia, Side Effect:Drug Toxicity": 2,
 "PK:dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA)": 2,
 "Efficacy:Thrombotic disease": 2,
 "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions": 2,
 "Other:levels of vitamin K-dependent proteins": 2,
 "Efficacy:occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy": 2,
 "Efficacy:shorter time to have over-anticoagulation (INR >4) risk": 2,
 "Other:platelet function": 2,
 "Side Effect:Interstitial Lung Diseases": 2,
 "Other:Neonatal hyperbilirubinemia": 2,
 "Efficacy:cortisol response": 2,
 "PK:exposure to drug": 2,
 "Side Effect:Hyponatremia": 2,
 "Efficacy:reduction in LDL-C": 2,
 "PK:achieving target concentrations": 2,
 "Side Effect:sensory peripheral neuropathy": 2,
 "Efficacy:difference in postprandial plasma glucose (before and after drug treatment)": 2,
 "Disease:Endometrial Neoplasms": 2,
 "Efficacy:antiplatelet effect": 2,
 "Efficacy:platelet aggregation values": 2,
 "Disease:Musculoskeletal pain": 2,
 "Efficacy:the time to achieve a first INR within the therapeutic range": 2,
 "Side Effect:total hemorrhage and major hemorrhage": 2,
 "Efficacy:Coronary Restenosis": 2,
 "Side Effect:Fever": 2,
 "Side Effect:cardiovascular events in patients undergoing PCI": 2,
 "Side Effect:Insomnia": 2,
 "Other:blood pressure": 2,
 "Disease:Abortion, Spontaneous": 2,
 "Efficacy:non-remission": 2,
 "Side Effect:Butyrylcholinesterase deficiency": 2,
 "PK:plasma free phenytoin concentration": 2,
 "Efficacy:Metastatic neoplasm": 2,
 "Side Effect:hypomagnesemia primary": 2,
 "Side Effect:Drug Toxicity, Side Effect:Muscular Diseases, Side Effect:Rhabdomyolysis, Side Effect:Toxic liver disease": 2,
 "PK:AUC0-12": 2,
 "Side Effect:dose decrease or switch to another cholesterol-lowering drug": 2,
 "Efficacy:significantly delayed time to inhibition of platelet aggregation (IPA)": 2,
 "Side Effect:triglycerides": 2,
 "PK:Piroxicam's area under the plasma concentration-time curve and decreased oral clearance": 2,
 "PK:clearance of S(+) mirtazapine": 2,
 "PK:diclofenac/5-hydroxydiclofenac urinary concentration ratio": 2,
 "PK:exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance": 2,
 "Efficacy:inhibitory effect on cyclooxygenase 1 activity": 2,
 "PK:paroxetine levels": 2,
 "PK:fluoxetine/(S)-norfluoxetine ratio": 2,
 "Other:weight regain after intentional weight loss": 2,
 "Side Effect:biopsy-proven acute rejection": 2,
 "Other:sensitivity in vitro": 2,
 "Side Effect:major cardiovascular events (MACE) rate": 2,
 "Side Effect:Dose reduction, Side Effect:Discontinuation": 2,
 "Side Effect:Ocular Hypertension": 2,
 "Side Effect:treatment-emergent suicidality": 2,
 "Side Effect:Arthralgia": 2,
 "Efficacy:delayed graft function": 2,
 "PK:Bosentan metabolism in vitro": 2,
 "PK:C/D ratio": 2,
 "Other:having warfarin Dose greater than 7.5 mg/day": 2,
 "PK:AUC of citalopram": 2,
 "Efficacy:non-response to aspirin": 2,
 "Efficacy:ADP-induced platelet aggregation": 2,
 "Side Effect:hepatotoxicty": 2,
 "Side Effect:total cholesterol": 2,
 "Side Effect:hematological toxicity": 2,
 "Side Effect:aspirin resistance": 2,
 "Side Effect:Dermatitis": 2,
 "Efficacy:complete response": 2,
 "PK:metabolic ratios of desipamine": 2,
 "Disease:Hemolysis": 2,
 "Side Effect:Diarrhea, Side Effect:Drug Toxicity, Side Effect:Hand-foot syndrome": 2,
 "Other:Neonatal Abstinence Syndrome": 2,
 "Other:survival": 2,
 "Side Effect:elevated insulin levels": 2,
 "Side Effect:Proteinuria": 2,
 "Disease:Inflammation": 2,
 "Side Effect:Stroke": 2,
 "Efficacy:risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients": 2,
 "Disease:Vomiting": 2,
 "Other:disease recurrence": 2,
 "Disease:Stomatitis": 2,
 "Side Effect:Cardiac rhythm disease, Side Effect:Cardiotoxicity": 2,
 "Other:length of hospital stay": 2,
 "Other:treatment": 2,
 "Side Effect:statin intolerance, defined primarily through muscle symptomatology": 2,
 "Side Effect:Gingival Overgrowth": 2,
 "Disease:Sleep Disorders": 2,
 "Other:craving": 2,
 "Efficacy:Transient Ischemic Attack, Efficacy:Stroke": 2,
 "Other:warfarin dose requirement in mechanical heart valve replacement patients": 2,
 "Other:Neonatal hyperbilirubinemia, Other:Hyperbilirubinemia": 2,
 "Other:Vitamin D Deficiency": 2,
 "Side Effect:Ataxia, Side Effect:Diplopia, Side Effect:Dizziness, Side Effect:Dysarthria": 2,
 "Side Effect:Craving": 2,
 "Other:Recurrence": 2,
 "Efficacy:reduction in pain": 2,
 "Other:use": 2,
 "PK:Serum anticholinergic activity": 2,
 "PK:formation of metabolites": 2,
 "Other:Methamphetamine dependence": 2,
 "Efficacy:percent reduction in LDL-cholesterol": 2,
 "PK:amitriptyline/nortriptyline ratio corrected for dose and weight": 2,
 "PK:area under curve (AUC) of omeprazole racemate, omeprazole sulfone, R-omeprazole and S-omeprazole": 2,
 "Disease:Schizophrenia": 2,
 "Side Effect:Sleep Disorders": 2,
 "Efficacy:high post-clopidogrel platelet reactivity": 2,
 "Efficacy:poorer reduction in low-density lipoprotein cholesterol (LDLc)": 2,
 "Other:same protective properties against angiotensin-converting enzyme inhibitors-induced cough": 2,
 "Disease:Alopecia": 2,
 "PK:intracellular and blood concentration": 2,
 "Side Effect:QTc prolongation": 2,
 "Efficacy:24-h excretion of calcium and decreased urinary volume": 2,
 "PK:dose-adjusted serum olanzapine concentrations": 2,
 "Other:smoking quantity, heaviness of smoking index and Fagerstrom test for nicotine dependence": 2,
 "Other:shorter bleeding time": 2,
 "Disease:Metabolic Syndrome": 2,
 "Efficacy:improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume": 2,
 "PK:serum hydrazine concentrations": 2,
 "Side Effect:delayed graft function": 2,
 "PK:metabolic ratio CIT/DCIT values and mean citalopram dose": 2,
 "PK:apparent terminal elimination half-life": 2,
 "PK:trough blood concentration": 2,
 "Efficacy:decreased chance of achieving 6 month abstinence in the placebo group": 2,
 "PK:exposure": 2,
 "Efficacy:cardiovascular events": 2,
 "Disease:Graft vs Host Disease": 2,
 "Side Effect:discontinuation": 2,
 "Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Side Effect:Pain": 2,
 "Side Effect:Anemia, Side Effect:Neutropenia, Side Effect:Pancytopenia, Side Effect:Thrombocytopenia": 2,
 "Side Effect:Epistaxis, Side Effect:Gastrointestinal Hemorrhage, Side Effect:Hematoma, Side Effect:Hematuria, Side Effect:Thrombotic disease": 2,
 "Disease:Overall survival": 2,
 "Efficacy:Elevated diastolic blood pressure, Efficacy:Elevated systolic blood pressure": 2,
 "Other:Transplant rejection": 2,
 "Side Effect:early major adverse cardiovascular events (MACE)": 2,
 "Side Effect:FEV1 decrease after aspirin challenge": 2,
 "PK:elevated plasma concentrations": 2,
 "Efficacy:lower warfarin dose requirement": 2,
 "Disease:Venous Thrombosis": 2,
 "Efficacy:reaction time": 2,
 "PK:minimum plasma concentrations": 2,
 "Other:bone mineral density": 2,
 "Side Effect:Death, Disease:Gastrointestinal Hemorrhage": 2,
 "Disease:Metabolic Bone Disorder, Disease:Osteoporosis": 2,
 "Side Effect:major  but not minor hemorrhage": 2,
 "Efficacy:ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention": 2,
 "Efficacy:ADP-induced maximum platelet aggregation": 2,
 "Efficacy:response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke": 2,
 "PK:mean amitriptyline concentrations corrected for dose and weight": 2,
 "Other:warfarin dose in Japanese patients": 2,
 "Efficacy:on-treatment platelet activity": 2,
 "Efficacy:shorter time to the first INR of more than 4": 2,
 "Disease:Edema": 2,
 "Side Effect:Peripheral Nervous System Diseases, Side Effect:Pain, Side Effect:Neuropathic pain": 2,
 "Efficacy:adverse outcome": 2,
 "Side Effect:Prolonged QTc interval": 2,
 "Side Effect:adverse drug reaction": 2,
 "Efficacy:acenocoumarol dose": 2,
 "PK:metabolic ratio CIT/DCIT values": 2,
 "Efficacy:on-treatment platelet aggregation": 2,
 "Efficacy:High on-treatment platelet reactivity": 2,
 "Efficacy:high on-treatment platelet reactivity in CYP2C19*1/*1 carriers": 2,
 "Other:hospital stay": 2,
 "PK:maximum plasma concentration of 10-hydroxy nortriptyline": 2,
 "Efficacy:clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI)": 2,
 "Side Effect:composite ischemic events": 2,
 "PK:oral clearance (CL/F) of omeprazole racemate, 5-hydroxyomeprazole, R-omeprazole and S-omeprazole": 2,
 "Side Effect:Gastrointestinal toxicity, Side Effect:Leukopenia": 2,
 "Disease:Peripheral Vascular Diseases": 2,
 "Side Effect:treatment-emergent suicidal ideation": 2,
 "PK:plasma efavirenz exposure": 2,
 "Side Effect:early (< 3 months) termination of efavirenz therapy": 2,
 "Efficacy:reduction in diastolic blood pressure": 2,
 "Side Effect:Anemia, Side Effect:Drug Toxicity": 2,
 "Side Effect:Memory impairment": 2,
 "Disease:Bradycardia": 2,
 "Side Effect:Jaundice": 2,
 "Efficacy:treatment emergent mania": 2,
 "Efficacy:treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients": 2,
 "Efficacy:anti-IFN-beta antibodies": 2,
 "PK:repaglinide exposure (decreased AUC and increased clearance)": 2,
 "Efficacy:higher mean peak INR during week 1 of warfarin therapy": 2,
 "Efficacy:increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy)": 2,
 "Efficacy:response time": 2,
 "Efficacy:higher P2Y12 reaction units (PRU) and lower percent inhibition": 2,
 "Disease:Fever": 2,
 "Side Effect:Left Ventricular Dysfunction": 2,
 "Side Effect:oedema": 2,
 "Efficacy:reduction in office diastolic blood pressure": 2,
 "Side Effect:Erythema": 2,
 "Other:time to therapeutic inr": 2,
 "Other:in-stent restenosis": 2,
 "Efficacy:non-response to clopidogrel": 2,
 "Efficacy:platelet responsiveness to clopidogrel": 2,
 "Disease:Fractures, Bone": 2,
 "Side Effect:Neutropenia, Side Effect:Thrombocytopenia": 2,
 "PK:nortriptyline concentrations corrected for dose and weight": 2,
 "Efficacy:response rate to pegIFN-alpha/RBV treatment at week 20/24": 2,
 "PK:Cmax of the active metabolite": 2,
 "Efficacy:platelet reactivity index (PRI) at 4 h after the dosing": 2,
 "Other:major adverse cardiovascular events": 2,
 "Disease:Pneumonitis": 2,
 "Efficacy:drug-resistance": 2,
 "PK:changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day)": 2,
 "Other:HDL cholesterol": 2,
 "Side Effect:gastrointestinal toxicities": 2,
 "Disease:Seizures": 2,
 "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia": 2,
 "Side Effect:Asthma": 2,
 "Efficacy:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine": 2,
 "PK:Cmax and AUC of venlafaxine": 2,
 "Efficacy:achieving a stable dose": 2,
 "Efficacy:frequency of remitters": 2,
 "PK:tramadol clearance in Chinese volunteers": 2,
 "Side Effect:Somnolence, Side Effect:Nausea, Side Effect:adverse events": 2,
 "Efficacy:reduction in fasting LDL-C": 2,
 "Other:cardiovascular death,myocardial infarction or stroke": 2,
 "PK:renal clearance and secretion clearance of metformin": 2,
 "PK:dose-adjusted plasma levels": 2,
 "Side Effect:Insulin Resistance": 2,
 "PK:red blood cell folate": 2,
 "PK:clearance of dicloxacillin": 2,
 "Efficacy:platelet inhibition after a clopidogrel 600-mg loading dose": 2,
 "PK:R-ibuprofen metabolism": 2,
 "Side Effect:drug-induced liver injury": 2,
 "Side Effect:fasting glucose": 2,
 "Side Effect:Side Effects": 2,
 "PK:dose-corrected plasma concentrations of fluoxetine": 2,
 "Efficacy:heart rate": 2,
 "Other:coffee consumption": 2,
 "Side Effect:Bradycardia": 2,
 "PK:plasma oxymorphone/oxycodone ratio": 2,
 "Efficacy:reduction in SBP": 2,
 "PK:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine": 2,
 "Other:Toxic liver disease": 2,
 "Other:ambulatory blood pressure": 2,
 "Side Effect:moderate anemia": 2,
 "Disease:Diarrhea, Disease:Nausea, Disease:Vomiting": 2,
 "Efficacy:reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3.": 2,
 "Disease:event-free survival, Disease:Overall survival": 2,
 "Efficacy:clopidogrel inhibition of ADP-induced platelet aggregation": 2,
 "Other:social withdrawal": 2,
 "Side Effect:Dizziness, Side Effect:Headache": 2,
 "PK:area under the plasma concentration-time curve": 2,
 "Efficacy:response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1": 2,
 "PK:6-MMPN levels": 2,
 "Other:Discontinuation, Other:Treatment modification": 2,
 "Other:spontaneous HCV clearance": 2,
 "Efficacy:reduction in total cholesterol and LDL-cholesterol": 2,
 "Other:acute rejection": 2,
 "Disease:Dry mouth": 2,
 "Side Effect:Dry mouth": 2,
 "Efficacy:more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation": 2,
 "PK:delayed cortisol response to stress": 2,
 "Side Effect:oral mucositis": 2,
 "Efficacy:percent change in FEV": 2,
 "PK:methotrexate polyglutamate (MTXPG3-5) levels": 2,
 "Other:overanticoagulation": 2,
 "Efficacy:relative inhibition of ADP-induced platelet aggregation": 2,
 "Disease:Peptic Ulcer Disease": 2,
 "Disease:Disorder of facial skeleton": 2,
 "Other:ACE activity": 2,
 "Side Effect:Psychotic Disorder": 2,
 "PK:plasma concentrations of rosuvastatin": 2,
 "Efficacy:clopidogrel resistance": 2,
 "Efficacy:Kidney Disorder": 2,
 "PK:total clearance of racemic mirtazapine": 2,
 "Disease:Hyperprolactinemia": 2,
 "Side Effect:Death, Side Effect:Myocardial Infarction, Side Effect:Stroke": 2,
 "Efficacy:on-clopidogrel platelet reactivity (HPR)": 2,
 "Efficacy:non-responsiveness": 2,
 "Disease:Anxiety Disorders": 2,
 "PK:area under the curve": 2,
 "Other:Aspirin-induced asthma": 2,
 "Efficacy:change in HDL-cholesterol": 2,
 "Side Effect:Elevated circulating creatine kinase concentration, Side Effect:Elevated liver enzymes": 2,
 "PK:concentration-to-adjusted dose ratio": 2,
 "Side Effect:adverse cognitive effects": 2,
 "Efficacy:Coronary Restenosis, Efficacy:Disease Progression": 2,
 "Side Effect:aspirin intolerance": 2,
 "Side Effect:Neutropenia, Side Effect:Discontinuation": 1,
 "PK:dose-adjusted AUC24": 1,
 "PK:achieving optimal trough level": 1,
 "Efficacy:improvement of depression symptoms": 1,
 "Other:interstitial inflammatory cell infiltration": 1,
 "PK:S-oxazepam glucuronidation in human liver microsomes": 1,
 "PK:oxazepam oral clearance": 1,
 "Disease:Hyperglycemia": 1,
 "Efficacy:staying in remission": 1,
 "PK:plasma concentrations of diflomotecan": 1,
 "Other:Neoplasms": 1,
 "Efficacy:pharmacodynamic response": 1,
 "PK:plasma exposure to the active metabolite of clopidogrel": 1,
 "Side Effect:diabetes": 1,
 "Efficacy:reaching target cholesterol levels": 1,
 "Other:later onset of sensory neuropathy": 1,
 "Efficacy:Mean spinal bone mineral density changes": 1,
 "Side Effect:adverse events, Side Effect:Physiological sexual disorder": 1,
 "Disease:Jaundice": 1,
 "PK:CYP3A4 acitvity": 1,
 "Other:progression-free survival and overall survival": 1,
 "Efficacy:platelet activation response to ADP": 1,
 "Efficacy:improvement in Anxiety-Depression symptoms": 1,
 "Side Effect:Exanthema, Side Effect:Alopecia, Side Effect:Hypersensitivity": 1,
 "Side Effect:appetite suppression": 1,
 "Efficacy:reduction in mean arterial pressure": 1,
 "Side Effect:Dyskinesia, Drug-Induced": 1,
 "Efficacy:Emergencies, Efficacy:Pain": 1,
 "Side Effect:Treatment modification": 1,
 "Other:Decreased glomerular filtration rate": 1,
 "Side Effect:hematological indices": 1,
 "PK:plasma levels": 1,
 "Side Effect:mortality": 1,
 "Other:P2Y12 reaction unit(PRU) values": 1,
 "Disease:Drug Toxicity, Disease:Infectious disease, Disease:Stomatitis": 1,
 "Side Effect:Uterine disorder, Side Effect:Leiomyoma, Side Effect:Endometrial Hyperplasia, Side Effect:Polyps": 1,
 "PK:differences in the fluvoxamine plasma level at 50 mg/day": 1,
 "PK:higher plasma concentrations of celecoxib": 1,
 "Efficacy:reduction in COX-1 inhibition and depression of the urinary thromboxane metabolite": 1,
 "Efficacy:reduction in COX-1 inhibition": 1,
 "Efficacy:absolute mean blood pressure": 1,
 "Side Effect:Diminished ability to concentrate": 1,
 "Side Effect:haematological toxicity or hepatotoxicity": 1,
 "Side Effect:Bone Marrow toxicity": 1,
 "Side Effect:overall ADRs": 1,
 "Side Effect:triglycerides in postmenopausal woman": 1,
 "Side Effect:in total cholesterol in postmenopausal woman and increase in triglycerides and decrease in high density lipoprotein in premenopausal women": 1,
 "PK:residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol": 1,
 "Side Effect:neurological ADR": 1,
 "Efficacy:5 year survival": 1,
 "Side Effect:Acute coronary syndrome": 1,
 "Side Effect:QTc interval": 1,
 "Efficacy:efficact as measured by lower pain relief to opioids": 1,
 "Other:Diabetes, Gestational": 1,
 "PK:dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide": 1,
 "Side Effect:grade III/IV liver toxicity": 1,
 "Other:Osteoarthritis": 1,
 "Side Effect:Hand-foot syndrome, Side Effect:Mucositis, Side Effect:Peripheral Nervous System Diseases": 1,
 "Efficacy:insufficient antiplatelet response to clopidogrel": 1,
 "PK:AUC 0-4 hours": 1,
 "Disease:Hepatitis C virus infection": 1,
 "Efficacy:efficacy as measured by decrease in HbA1c": 1,
 "Other:Non-Small Cell Lung Carcinoma": 1,
 "Other:significantly shorter survival": 1,
 "Disease:Leukemia": 1,
 "Side Effect:Death, Side Effect:Myocardial Infarction": 1,
 "Other:platelet aggregation with ADP": 1,
 "Side Effect:extrapyramidal symptoms, Side Effect:Tremor, Side Effect:Muscle Rigidity": 1,
 "Side Effect:Psychomotor Agitation, Side Effect:Insomnia": 1,
 "PK:dose/weight adjusted AUC for mirtazapine": 1,
 "Efficacy:beta cell function": 1,
 "PK:insulin secretion at baseline": 1,
 "PK:citalopram AUC and terminal elimination half-life": 1,
 "Side Effect:Recurrence": 1,
 "PK:median concentration/dose ratio and median parent drug/metabolite ratio": 1,
 "Disease:Breast tenderness, Disease:Vaginal dryness, Disease:Vomiting": 1,
 "Efficacy:lack of treatment response": 1,
 "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms": 1,
 "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea": 1,
 "Efficacy:Myocardial Infarction, Efficacy:Angina Pectoris": 1,
 "Disease:Hypokalemia": 1,
 "Side Effect:Sexual adverse events": 1,
 "Efficacy:Status asthmaticus": 1,
 "Efficacy:Recurrence free survival, Efficacy:Overall survival": 1,
 "Side Effect:CNS depression": 1,
 "Disease:Oligospermia": 1,
 "Efficacy:remission if tolerant to citalopram treatment": 1,
 "Side Effect:Parkinsonian Disorder, Side Effect:Tardive Dyskinesia": 1,
 "Side Effect:Nail disorder": 1,
 "Efficacy:response and remission rate": 1,
 "PK:6-TG levels": 1,
 "PK:creatinine clearance": 1,
 "Efficacy:on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI)": 1,
 "Side Effect:Drug Toxicity, Disease:Hand-foot syndrome": 1,
 "Efficacy:time to respond": 1,
 "Side Effect:adverse outcome": 1,
 "Efficacy:efficacy as measured by decrease in HbA1c after 6-month treatment": 1,
 "Efficacy:earlier achievement of blood pressure control": 1,
 "Efficacy:Coronary Restenosis, Side Effect:Thrombotic disease": 1,
 "Efficacy:Major Adverse Cardiac Events (MACE), Efficacy:Death, Efficacy:Myocardial Infarction, Efficacy:Stroke, Side Effect:Unstable Angina": 1,
 "Side Effect:Thyrotoxicosis, Side Effect:Hypothyroidism": 1,
 "Side Effect:hemoglobin levels": 1,
 "Other:asthma exacerbations": 1,
 "Other:recurrence-free survival": 1,
 "Side Effect:Cataract": 1,
 "Efficacy:time until response": 1,
 "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder": 1,
 "Side Effect:Discontinuation, Side Effect:Weight gain": 1,
 "Efficacy:magnitude of platelet reactivity": 1,
 "Side Effect:cardiovascular event": 1,
 "Efficacy:dosage requirement": 1,
 "Side Effect:a mild increase of liver enzymes": 1,
 "Efficacy:asthma exacerbations": 1,
 "Other:total cholesterol": 1,
 "PK:Oxycodone consumption up to the 12(th) hour in postoperative patients": 1,
 "Efficacy:blood pressure response": 1,
 "Efficacy:Bispectral Index and Ramsay Sedation Scores, indicating a longer period for falling asleep": 1,
 "Side Effect:Nephrotoxicity, Side Effect:Tremor, Side Effect:Diabetes Mellitus": 1,
 "Efficacy:improvement in left ventricular(LV) remodeling": 1,
 "Other:sensitivity to etoposide": 1,
 "Efficacy:frequency of patients who received at least the recommended 80% of scheduled ribavirin": 1,
 "Efficacy:cumulative reduction of ribavirin": 1,
 "PK:adjusted trough concentrations": 1,
 "Efficacy:dose requirement": 1,
 "Side Effect:serious hypersensitivity": 1,
 "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Exanthema, Side Effect:Stevens-Johnson Syndrome": 1,
 "Efficacy:achieving SVR in older patients with genotype 1b chronic hepatitis C": 1,
 "Efficacy:the most benefit from statin treatment in reducing the risk of myocardial infarction": 1,
 "Disease:Virus Diseases": 1,
 "Efficacy:allograft rejection": 1,
 "Efficacy:tonic block of Na(V) 1.1 channels": 1,
 "Other:erythromycin transport": 1,
 "Side Effect:drug-drug pharmacokinetic interaction": 1,
 "Side Effect:clomipramine-induced prolactin release": 1,
 "Efficacy:presentation in the non-reponder group": 1,
 "Side Effect:severe cutaneous adverse drug reactions": 1,
 "Side Effect:ischaemic stroke": 1,
 "Efficacy:PRU": 1,
 "Side Effect:major adverse cardiovascular events": 1,
 "Efficacy:cardiovascular event occurrence": 1,
 "Side Effect:adverse events, Side Effect:Exanthema": 1,
 "PK:levels of erythrocyte 6-thioguanine nucleotide metabolites": 1,
 "Side Effect:Hearing Loss": 1,
 "Efficacy:Transient Ischemic Attack, Efficacy:Death, Efficacy:Stroke, Efficacy:Myocardial Infarction": 1,
 "Efficacy:Heart Failure, Efficacy:Myocardial Infarction, Efficacy:Angina Pectoris": 1,
 "PK:HDL-C concentration": 1,
 "PK:AUC of the S-enantiomer of citalopram (no effect on R-CT)": 1,
 "Side Effect:Headache, Side Effect:Muscle spasm, Side Effect:Somnolence, Side Effect:Dizziness": 1,
 "Side Effect:Neutropenia, Side Effect:Diarrhea, Side Effect:Stomatitis, Side Effect:Leukopenia, Side Effect:Nausea, Side Effect:Vomiting": 1,
 "Disease:Hematologic Disorder": 1,
 "Efficacy:Status asthmaticus, Efficacy:Emergencies": 1,
 "Efficacy:bronchodilator response (BDR)": 1,
 "Efficacy:Death, Efficacy:Recurrence": 1,
 "Side Effect:Cystitis": 1,
 "Side Effect:Diarrhea, Side Effect:Neutropenia": 1,
 "Side Effect:Discontinuation, Side Effect:Drug Toxicity, Side Effect:Neutropenia, Side Effect:Diarrhea": 1,
 "Side Effect:Neutropenia, Side Effect:Febrile neutropenia, Side Effect:Leukopenia": 1,
 "Side Effect:gastrointestinal disturbances in HCV-HIV coinfected patients": 1,
 "Efficacy:rapid virological response (RVR) in HCV-HIV coinfected patients": 1,
 "Efficacy:weight loss": 1,
 "Side Effect:Neutropenia in HCV-HIV coinfected patients": 1,
 "PK:metabolic ratio of midazolam": 1,
 "Efficacy:response to methotrexate": 1,
 "Efficacy:response (SVR and RVR) in HCV-HIV coinfected patients": 1,
 "Other:stop reaction time": 1,
 "Disease:Prostatic Neoplasms": 1,
 "Efficacy:antibody-dependent cellular cytotoxicity": 1,
 "Side Effect:GI intolerance": 1,
 "Side Effect:Drug Toxicity, Side Effect:Neutropenia": 1,
 "Efficacy:high on-treatment platelet reactivity, Efficacy:Major Adverse Cardiac Events (MACE)": 1,
 "Efficacy:Postoperative Nausea and Vomiting": 1,
 "Side Effect:Discontinuation, Side Effect:adverse events": 1,
 "Side Effect:neurotoxicity": 1,
 "Efficacy:Peripheral Vascular Diseases": 1,
 "Side Effect:Virus Diseases": 1,
 "Side Effect:low-density lipoprotein cholesterol": 1,
 "Side Effect:Atrial Fibrillation": 1,
 "Side Effect:Decreased glomerular filtration rate": 1,
 "Side Effect:Musculoskeletal pain": 1,
 "Side Effect:Stevens-Johnson Syndrome, Side Effect:Erythema multiforme": 1,
 "Side Effect:Somnolence, Side Effect:Dizziness, Side Effect:Drug Toxicity": 1,
 "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Drug-induced liver injury": 1,
 "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Maculopapular Exanthema, Side Effect:Drug Hypersensitivity, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Erythema multiforme": 1,
 "Side Effect:high on-treatment platelet reactivity": 1,
 "Side Effect:Dizziness, Side Effect:Somnolence": 1,
 "Efficacy:low-density lipoprotein cholesterol level in basal state and possibly in response to atorvastatin.": 1,
 "Side Effect:Neutropenia, Side Effect:Diarrhea": 1,
 "Side Effect:Leukopenia, Side Effect:Myelosuppression": 1,
 "Efficacy:Death, Efficacy:Stroke, Efficacy:Heart Failure, Efficacy:Myocardial Infarction": 1,
 "PK:AUC, higher half-life and lower flurbiprofen clearance": 1,
 "PK:plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT)": 1,
 "PK:exposure to timolol (higher area-under-curve, longer elimination half-lives )": 1,
 "PK:AUC and half-life time (t1/2)": 1,
 "Side Effect:iNOS expression and fewer adverse events": 1,
 "Efficacy:response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels)": 1,
 "Efficacy:change in sweat chloride": 1,
 "Efficacy:on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI)": 1,
 "Other:meal-stimulated plasma gastrin concentrations": 1,
 "PK:mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio": 1,
 "PK:paroxetine plasma concentration at an administered dose of 30mg/day": 1,
 "PK:shorter continin half-life": 1,
 "PK:oral clearance of citalopram": 1,
 "PK: plasma paroxetine concentrations at administered dose of 10mg/day": 1,
 "PK:codeine metabolism and morphine and glucuronides formation": 1,
 "PK:plasma level of morphine": 1,
 "Side Effect:glucose elevation": 1,
 "Side Effect:Sepsis, Side Effect:Seizures, Side Effect:Nephrotoxicity": 1,
 "Efficacy:significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily": 1,
 "Side Effect:Drug Toxicity, Side Effect:Treatment interruption": 1,
 "Other:spine Bone Mineral Density": 1,
 "Efficacy:mean INR value": 1,
 "Efficacy:On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI)": 1,
 "Efficacy:tramadol metabolism and response": 1,
 "Side Effect:discontinuations due to adverse events and greater severity of side effects": 1,
 "Efficacy:good response to controlled ovarian hyperstimulation": 1,
 "PK:plasma MK-4 concentration": 1,
 "Efficacy:Bone Mineral Density": 1,
 "Efficacy:reduction in fasting IL-2": 1,
 "Other:warfarin sensitivity index (INR/Cpss)": 1,
 "Efficacy:urinary DPD/Cr levels": 1,
 "Side Effect:Hyperuricemia": 1,
 "Side Effect:serum creatine kinase levels (increased risk of myalgia and greater degree of muscle damage)": 1,
 "PK:lower nevirapine plasma concentrations": 1,
 "Side Effect:carbamazepine-induced hypersensitivity": 1,
 "Side Effect:carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)": 1,
 "Side Effect:Carbamazepine-induced hypersensitivity syndrome": 1,
 "Efficacy:enhanced response to clopidogrel (as measured by inhibition of ADP-induced platelet aggregation)": 1,
 "Side Effect:phenytoin toxicity": 1,
 "PK:plasma thioguanine nucleotides metabolites": 1,
 "PK:plasma concentration of efavirenz": 1,
 "PK:plasma fluorouracil": 1,
 "Side Effect:liver injury": 1,
 "Disease:Drug Resistance": 1,
 "PK:atorvastatin lactonization": 1,
 "Efficacy:total and the low-density lipoprotein cholesterol maximum percent decreases from baseline": 1,
 "Efficacy:mean absolute difference in HbA1c": 1,
 "PK:relative bioavailability of pravastatin": 1,
 "Other:Euphoric and Energetic after amphetamine (10 mg)": 1,
 "Efficacy:treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype": 1,
 "Side Effect:Diarrhea, Side Effect:Vomiting": 1,
 "Efficacy:Parasitemia": 1,
 "Efficacy:non-response to methotrexate": 1,
 "Efficacy:shorter time to first therapeutic INR and time to first INR>4": 1,
 "Side Effect:Angioedema, Side Effect:Urticaria": 1,
 "Efficacy:propertion of the first 6 months' treatment time spent within the target INR range (PTIR)": 1,
 "PK:plasma levels of morphine, M3G and M6G levels but not those of codeine": 1,
 "Other:oroceccal transit time": 1,
 "Efficacy:less robust treatment response": 1,
 "Efficacy:frequency (about double) in non-responder patients compared with responder patients (HCV genotype 4)": 1,
 "Side Effect:Hand-foot syndrome, Side Effect:Neutropenia": 1,
 "Side Effect:Erectile Dysfunction, Side Effect:Insomnia, Side Effect:sedation, Side Effect:Physiological sexual disorder, Side Effect:Vomiting": 1,
 "Other:warfarin variability": 1,
 "Other:Stimulation and Euphoria scores after amphetamine": 1,
 "Side Effect:Anemia, Side Effect:Thrombocytopenia, Side Effect:Neutropenia": 1,
 "Other:short and long-term weight loss": 1,
 "PK:being a predictor of mitotane plasma concentrations of at least 14 \u00b5g/ml after 3 months of treatment": 1,
 "Side Effect:earlier onset of bortezomib-induced peripheral neuropathy": 1,
 "PK:PBMC-associated drug concentrations": 1,
 "PK:baseline cortisol levels": 1,
 "PK:intracellular PBMC exposure": 1,
 "Other:Helicobacter pylori infection": 1,
 "Side Effect:Tremor": 1,
 "Efficacy:worse outcome (overall survival and progression-free survival)": 1,
 "Efficacy:pharmacological resistance": 1,
 "PK: area under the plasma concentration-time curve": 1,
 "PK:plasma concentration (p<0.001)": 1,
 "PK:plasma concentration (p=0.028)": 1,
 "Efficacy:reduction in LDL": 1,
 "Disease:Ventricular Fibrillation": 1,
 "Other:5% lower ADP-induced peak platelet aggregation in-vitro": 1,
 "Other:Chronic lung allograft dysfunction": 1,
 "PK:25% higher mean 4'-desmethyl OLA/olanzapine (OLA) ratio": 1,
 "Efficacy:low on-treatment platelet reactivity": 1,
 "Efficacy:lipid-lowering effect": 1,
 "Side Effect:motor side effects": 1,
 "PK:29% lower mean 4'-desmethyl OLA/olanzapine (OLA) ratio": 1,
 "PK:impaired metabolic activity": 1,
 "Other:complications": 1,
 "Other:warfarin dose after adjustment for VKORC1*1173": 1,
 "Side Effect:muscle effects": 1,
 "Efficacy:mean INR values in patients with heart valve replacement": 1,
 "Efficacy:Neuropathic pain": 1,
 "Side Effect:Methamphetamine dependence": 1,
 "Side Effect:Asthma-related ER visit or hospitalization": 1,
 "Efficacy:mean percentage reduction of triglycerides level": 1,
 "Disease:Asthenia": 1,
 "Side Effect:Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors": 1,
 "PK:plasma concentrations of metoprolol": 1,
 "Side Effect:adverse drug reaction after the second switch in treatment": 1,
 "PK:amitriptyline/(E)-10- OH-AT ratio": 1,
 "PK:nortriptyline/(E)-10-OH-NT ratio": 1,
 "Side Effect:hematotoxicity": 1,
 "PK:mid-dose plasma concentrations": 1,
 "Efficacy:duration of inhibition of prostanoids": 1,
 "PK:the maximal elimination rate (Vmax)": 1,
 "PK:elimination rate": 1,
 "PK:plasma methylmercaptopurine nucleotides levels": 1,
 "PK:hydroxybupropion concentrations": 1,
 "Side Effect:cutaneous reactions": 1,
 "PK:clerance of paclitaxel": 1,
 "PK:hydroxybupropion concentrations and hydroxybupropion/bupropion ratio": 1,
 "Other:Hypertriglyceridemia": 1,
 "Other:mortality after myocardial infarction, however this can be eliminated": 1,
 "Side Effect:time below therapeutic range": 1,
 "Other:weight": 1,
 "PK:steady state concentration per dosage": 1,
 "Side Effect:stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI)": 1,
 "PK:paroxetine serum concentrations (Cmin)": 1,
 "Side Effect:diphenylhydantoin-induced skin rash": 1,
 "Other:ADP-stimulated platelet aggregation": 1,
 "Efficacy:Myocardial Infarction, Efficacy:Recurrence": 1,
 "Disease:Iron Overload": 1,
 "PK:renal and secretory clearance of metformin": 1,
 "PK:oral clearance of atorvastatin": 1,
 "PK:accumulation of drug in PBMCs": 1,
 "Side Effect:Skin Disorder": 1,
 "PK:area under plasma concentration of propranolol": 1,
 "Efficacy: VASP index": 1,
 "Side Effect:decline in FEV 1 after aspirin provocation": 1,
 "Side Effect:atherothrombotic events during the 6-year follow up in patients with mechanical heart valve replacement": 1,
 "Other:warfarin dose during 3-month daily observation period in patients with mechanical heart valve replacement": 1,
 "PK:elimination clearance of dFdU and formation clearance of dFdCTP": 1,
 "PK:formation clearance of dFdCTP": 1,
 "PK:elimination clearance of dFdU": 1,
 "Other:biochemical response, optimal cytoreduction, and sensitivity to the induction chemotherapy treatment": 1,
 "Disease:Diabetes Mellitus, Type 2": 1,
 "Side Effect:Diarrhea, Side Effect:Mucositis, Side Effect:Neutropenia": 1,
 "Side Effect:aspirin hypersensitivity": 1,
 "Side Effect:nephrotoxicity": 1,
 "Efficacy:mean INR during 3-month daily observation period in patients with mechanical heart valve replacement": 1,
 "Efficacy:number of examinations above the therapeutic range during 3-month daily observation period in patients with mechanical heart valve replacement": 1,
 "Efficacy:time to therapeutic INR>=2": 1,
 "Other:stable warfarin dose": 1,
 "Side Effect:Coronary Disease": 1,
 "Side Effect:bleeding complications": 1,
 "Efficacy: rate of hyper-response at 1 month of treatment": 1,
 "PK:mitotane plasma concentrations": 1,
 "Side Effect:Diarrhea, Side Effect:Exanthema": 1,
 "Side Effect:bone marrow toxicity": 1,
 "Other:systolic (SAP) and diastolic (DAP) arterial pressure responses to timolol": 1,
 "Side Effect:Hypotensive disorder": 1,
 "PK:mean AUC": 1,
 "Side Effect:all statin-induced myopathy and severe myopathy": 1,
 "Efficacy:nonresponse to anti-EGFR-based treatment": 1,
 "Side Effect:severe hearing impairment": 1,
 "Efficacy:Cocaine dependence": 1,
 "Other:dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction": 1,
 "Efficacy:platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment": 1,
 "Efficacy: rate of high on-treatment platelet reactivity (HTPR) at 1 month of treatment": 1,
 "Other:inhibition of CYP3A-catalyzed metabolism of midazolam or testosterone": 1,
 "Efficacy:protection against myocardial infarction": 1,
 "Side Effect:renal function (lower creatinine clearance) at 3 months of follow-up": 1,
 "PK:CL renal reference and lower and CL sec reference": 1,
 "Other:statin doses for optimal lipid control": 1,
 "Other:hydrochlorothiazide induced calcium retention": 1,
 "Disease:Hepatic Veno-Occlusive Disease": 1,
 "Efficacy:anti-inflammatory effects": 1,
 "Other:Blood Coagulation Disorders": 1,
 "PK:tolterodine exposure and increased active metabolite (5-HM) concentrations": 1,
 "Side Effect:Gastritis": 1,
 "PK:plasma metoprolol concentrations": 1,
 "Efficacy:mortality": 1,
 "Side Effect:Cystic fibrosis pulmonary exacerbation": 1,
 "Side Effect:severe leukopenia": 1,
 "Other:heart rate (HR) and diastolic blood pressure (DBP) reductions during early titration": 1,
 "PK:significantly higher (S)-fluoxetine and lower and (S)-norfluoxetine concentrations": 1,
 "PK:dose-corrected plasma concentrations of fluoxetine and the active moiety in patients with two functional CYP2D6 alleles": 1,
 "PK:concentrations of 10-OH-nortriptyline and higher nortriptyline/10-OH-nortriptyline ratio": 1,
 "Efficacy:reduction in D-dimer levels": 1,
 "PK:plasma timolol concentration and excerice heart rate reduction": 1,
 "Efficacy:reduction in IL-6 levels": 1,
 "Efficacy:reduction in CRP levels": 1,
 "Side Effect:average cumulative neurotoxicity grade": 1,
 "Side Effect:Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic": 1,
 "Other:all-cause mortality": 1,
 "Side Effect:Agranulocytosis, Side Effect:Neutropenia": 1,
 "Side Effect:mean cumulative doses of isoniazid before the development of abnormal liver-function tests (ALFTs)": 1,
 "Efficacy:Disease Activity": 1,
 "Side Effect:mean cumulative doses of isoniazid before the development of antituberculosis drug-induced hepatotoxicity (ATDIH)": 1,
 "Efficacy:improved asthma control (as measured by decrease in average asthma control score)": 1,
 "PK:trough blood concentration normalized for the daily dose (C) per kilogram body weight (D) (C/D, ng/ml/mg/kg/day) ratio during the first month after transplantation": 1,
 "Side Effect:Long QT Syndrome": 1,
 "Other:concentrations of S-citalopram and metabolic ratio of of S-desmethylcitalopram/citalopram": 1,
 "Other:greater heart rate (HR) reduction": 1,
 "Other:High Platelet Reactivity (HPR)": 1,
 "Other:a correlation of brain SERT occupancy was associated with larger proportional HDRS17 decreases": 1,
 "Other:bone marrow density in the lumbar spine": 1,
 "Other:Disease-Free Survival": 1,
 "Other:methylation at sites 1 and 2 in the COMT promoter": 1,
 "Efficacy:response to chemotherapy": 1,
 "PK:time to achieve therapeutic window": 1,
 "PK:S-CIT serum concentrations": 1,
 "PK:mean escitalopram concentration": 1,
 "Efficacy:response when measured by the Geriatric Depression Scale at day 7 and day 28": 1,
 "Side Effect:lower final daily dose, decreased dosing compliance and lower plasma levels at day 28": 1,
 "Efficacy:positive correlation of paroxetine concentration with improvement in HAMD scores at week 2": 1,
 "PK:demethylation clearance of desmethylcitalopram": 1,
 "Disease:Atrial Fibrillation": 1,
 "Efficacy: aspirin-resistant phenotype": 1,
 "Efficacy:median weekly warfarin dose requirements": 1,
 "Side Effect:myalgia": 1,
 "Efficacy:reduction in resting blood pressure": 1,
 "Side Effect:obesity": 1,
 "Side Effect:aspirin-intolerant chronic urticaria": 1,
 "Efficacy:sen sitivity to warfarin during induction": 1,
 "Other:whole blood nitrite": 1,
 "Side Effect:Anemia, Side Effect:Mucositis": 1,
 "Efficacy:higher platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment": 1,
 "Side Effect:Anemia, Side Effect:Neutropenia": 1,
 "Side Effect:Abdominal Pain": 1,
 "PK: serum R -warfarin concentration": 1,
 "Side Effect:diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment": 1,
 "Disease:Proteinuria": 1,
 "PK:racemic, S-ibuprofen and R-ibuprofen metabolism, with increase of AUC(0-infinity) and reduction of clearance": 1,
 "PK:plasma 4beta-OHC/Chol ratio": 1,
 "PK:plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT)": 1,
 "Other:iNOS expression": 1,
 "Other:plasma concentration of S-didesmethyl-citalopram": 1,
 "PK:mean logarithm escitalopram concentration and higher mean metabolic ratio": 1,
 "Side Effect:Fever, Side Effect:Mucositis": 1,
 "Efficacy:minimal residual disease": 1,
 "\"Efficacy:primary graft failure\", \"Efficacy:Kidney Tubular Necrosis, Acute\"": 1,
 "Side Effect:Sepsis": 1,
 "Side Effect:nephrotoxicity grades 1-4": 1,
 "Side Effect:hemorrhagic transformation": 1,
 "Other:Metastatic neoplasm": 1,
 "Side Effect:requirement for earlier dose reduction of ribavirin": 1,
 "Efficacy:high platelet reactivity": 1,
 "Side Effect:Heparin-induced thrombocytopenia": 1,
 "Side Effect:cardiovascular events (composite of cardiac death, MI, stent thrombosis) in Korean patients after PCI": 1,
 "Efficacy:blunting of alcohol craving": 1,
 "Efficacy:higher rate of sustained virological response (SVR)": 1,
 "Side Effect:Alopecia, Side Effect:Leukopenia": 1,
 "Other:expression of enzyme contributing to the metabolism": 1,
 "Other:Pre-Eclampsia": 1,
 "Efficacy:intoxication": 1,
 "Side Effect:Hyperalgesia": 1,
 "Efficacy:FEV1/FVC ratio": 1,
 "Other:erythrocyte plasma membrane fluidity": 1,
 "PK:S-warfarin clearance": 1,
 "PK:venlafaxine concentration per unit dose": 1,
 "Efficacy:mean AUC (area under curve) prothrombin time": 1,
 "Other:small-dense LDL levels": 1,
 "Side Effect:Infectious disease, Side Effect:Leukopenia": 1,
 "Side Effect:intolerability": 1,
 "Disease:Dyskinesias": 1,
 "Disease:Hallucinations": 1,
 "Disease:Venous thromboembolism": 1,
 "Efficacy:one year progression free survival": 1,
 "Side Effect:flu-like symptoms": 1,
 "Efficacy:numerical rating scale (NRS) score for pain during painful procedure": 1,
 "Efficacy:overall mean numerical rating scale (NRS) score for pain": 1,
 "Side Effect:Mucositis, Side Effect:Neutropenia, Side Effect:Pancreatitis, Side Effect:Vomiting": 1,
 "Other:20% and 17% less inhibition of platelet aggregation with crangrelor (0.05 and 0.25 microM) in-vitro": 1,
 "Efficacy:poor response": 1,
 "Efficacy:tumor response rate": 1,
 "Side Effect:interval of therapy to leukopenia onset": 1,
 "PK:prolonged high concentrations": 1,
 "Side Effect:Folic Acid Deficiency Anemia": 1,
 "Side Effect:sexsual dysfunction": 1,
 "Side Effect:non-HDL cholesterol": 1,
 "PK:glucuronidation of nicotine": 1,
 "PK:nicotine glucuronidation": 1,
 "Disease:Kidney Failure": 1,
 "Disease:Obesity": 1,
 "Efficacy:response (heart-rate lowering)": 1,
 "Efficacy:reduced progression-free survival": 1,
 "Side Effect:dose reductions due to toxicity": 1,
 "Efficacy:Heart transplantation, Efficacy:Death": 1,
 "Other:platelet aggregation with epinephrine": 1,
 "Side Effect:hearing and vision-related side-effects": 1,
 "Side Effect:general side-effect burden": 1,
 "Efficacy:stronger aggreagtion": 1,
 "Efficacy:net decrease in AA-induced platelet aggregation after aspirin treatment": 1,
 "Disease:Gastrointestinal Hemorrhage": 1,
 "PK:mean plasma AUC": 1,
 "Efficacy:Alcohol abuse": 1,
 "Efficacy:better clinical response": 1,
 "PK:Unbound oral clearance for S-warfarin": 1,
 "Efficacy:HAM-D score changes in fluvoxamine-treated patients compared to paroxetine-treated patients": 1,
 "Other:wakefulness activity level": 1,
 "Other:tumor size": 1,
 "Other:oxidative stress": 1,
 "PK:time to reach stable dose of tacrolimus": 1,
 "PK:dose of tacrolimus": 1,
 "Efficacy:sustained virological response (SVR)": 1,
 "Other:non-fatal myocardial infarction,stroke, revascularization or death": 1,
 "Side Effect:higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up": 1,
 "Other:lymph node involvement": 1,
 "Efficacy:median survival time": 1,
 "Side Effect:Cardiomyopathies": 1,
 "Efficacy:successful rhythm control": 1,
 "Efficacy:survival time": 1,
 "Disease:Ischemia": 1,
 "Other:dose decrease or drug switching": 1,
 "PK:Mean oxymorphone/oxycodone ratios": 1,
 "Disease:Hypotensive disorder": 1,
 "PK:steady-state plasma concentrations of desipramine/daily dose of desipramine/body weight": 1,
 "Other:Recurrence free survival": 1,
 "Efficacy:worse prognosis (overall survival and progression-free survival) in patients who were ER-ve/PR-ve negative": 1,
 "PK:M-III:pioglitazone AUC0-48 ratio and M-III:M-IV AUC0-48 ratio in healthy African-American volunteers": 1,
 "Side Effect:osteonecrosis": 1,
 "Efficacy:change in total cholesterol": 1,
 "Disease:Headache": 1,
 "Side Effect:grade 3-4 nonhematological toxicity": 1,
 "Side Effect:dose reduction": 1,
 "Side Effect:Gastrointestinal toxicity, Side Effect:Hematologic Disorder, Side Effect:Leukopenia": 1,
 "Efficacy:rise in CD4-cell count": 1,
 "Efficacy:favorable virologic responses": 1,
 "Efficacy:reduction in LDLc": 1,
 "Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia": 1,
 "PK:blood pressure": 1,
 "Side Effect:plasma triglycerides": 1,
 "Side Effect:Anxiety Disorders": 1,
 "Efficacy:brief psychiatric rating scale scores": 1,
 "Efficacy:Craving": 1,
 "Other:tacrolimus nephrotoxicity": 1,
 "Efficacy:positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype": 1,
 "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm": 1,
 "Disease:Torsades de Pointes": 1,
 "Efficacy:percentage change in LDL-cholesterol levels": 1,
 "PK:log metabolic ratio of amitriptyline/nortriptyline": 1,
 "Efficacy:clinical response": 1,
 "PK:resistance": 1,
 "Efficacy:induction failure": 1,
 "Disease:Gingival Hyperplasia": 1,
 "Efficacy:acute rejection": 1,
 "PK:significantly larger mean AUC of oseltamivir, lower Cmax of oseltamivir carboxylate, and a smaller oseltamivir carboxylate-to-oseltamivir AUC ratio": 1,
 "PK:PBMC concentrations": 1,
 "Side Effect:Sleep Initiation and Maintenance Disorders": 1,
 "Efficacy:improvements in neurovegetative symptoms": 1,
 "Other:Down Syndrome": 1,
 "PK:duodenal absorption of digoxin after direct delivery to the surface of the duodenum by endoscope": 1,
 "PK:time to reach stable dose": 1,
 "Other:emergency department and hospital utliization": 1,
 "Side Effect:Cushing Syndrome": 1,
 "Other:emergency department utliization": 1,
 "Side Effect:baseline adiponectin and with greater adiponectin decline": 1,
 "Other:Emergencies": 1,
 "Side Effect:Autonomic Nervous System Disorder": 1,
 "PK:glucuronidated metabolites of olanzapine": 1,
 "Efficacy: ADP-induced on treatment platelet aggregation (OTPR)": 1,
 "PK:dose-normalized  Cmax and dose-normalized  AUC0to12 h": 1,
 "Other:event-free survival": 1,
 "Efficacy:having INR above target range in week 1": 1,
 "Side Effect:Drug Toxicity, Side Effect:Nephrotoxicity": 1,
 "PK:systemic exposure (AUC) and lower oral clearance of flecainide": 1,
 "Other:a more rapid attainment of target INR and higher frequency of dose adjustments": 1,
 "Other:cardiovascular events": 1,
 "Side Effect:end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance.": 1,
 "Side Effect:prolonged QTc": 1,
 "PK:(S)-methadone plasma levels": 1,
 "Side Effect:being overanticoagulated": 1,
 "PK:sterol/bile acid metabolites": 1,
 "Side Effect:prolactin concentrations": 1,
 "PK:areas under the serum concentration-time curve": 1,
 "Other:inosine monophosphate dehydrogenase activity": 1,
 "Efficacy:response base on Disease Activity Score in 44 joints improvement at 6 months of treatment": 1,
 "Efficacy: disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints": 1,
 "Efficacy:prostate cancer-specific mortality": 1,
 "Other:maintenance dose of warfarin": 1,
 "Other:Substance Withdrawal Syndrome": 1,
 "Efficacy:time in therapeutic range of INR (TTR)": 1,
 "Disease:Anemia, Disease:Neutropenia": 1,
 "Disease:Epilepsy": 1,
 "Other:subclinical allograft nephropathy": 1,
 "Efficacy:reduction in DNA damage": 1,
 "Efficacy:greater positive symptom improvement and positive symptom remission": 1,
 "Efficacy:positive response": 1,
 "Efficacy:treatment response": 1,
 "Efficacy:frequency of rescue analgesic administration": 1,
 "Side Effect:relapse of psychosis": 1,
 "Side Effect:overall gastrointestinal toxicity": 1,
 "PK:the mean maximal elimination rates (V(max))": 1,
 "PK:in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein": 1,
 "Side Effect:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome": 1,
 "Side Effect:cardiac damage": 1,
 "Side Effect:bleeding time": 1,
 "Efficacy:prophylactic treatment response": 1,
 "PK:unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio": 1,
 "Side Effect:ADR": 1,
 "Side Effect:Bone Marrow Disorder, Side Effect:Toxic liver disease": 1,
 "Efficacy:overall survival and time-to-treat failure": 1,
 "Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Cognitive disorder, Side Effect:Constipation, Side Effect:adverse events": 1,
 "Efficacy:Hyperlipidemias": 1,
 "Efficacy:changes in FEV1": 1,
 "Side Effect:Primary ovarian failure": 1,
 "Side Effect:Agranulocytosis, Side Effect:Leukopenia": 1,
 "PK:the intrinsic metabolic activity (V(max)/K(m))": 1,
 "Efficacy:Overall survival (OS) time": 1,
 "Side Effect:primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis": 1,
 "PK:intracellular tenofovir diphosphate (TFV-DP) concentrations": 1,
 "Side Effect:Pain, Side Effect:Diarrhea": 1,
 "PK:non-inducible thiotepa clearance and decreased tepa clearance": 1,
 "PK:tenofovir renal clearance, and lower AUC": 1,
 "Other:Diabetes Mellitus, Type 2": 1,
 "Side Effect:Bone Marrow Disorder": 1,
 "Side Effect:Sleep Apnea Syndromes": 1,
 "Other:cardiac rehospitalization": 1,
 "Other:Attention Deficit Disorder with Hyperactivity": 1,
 "Efficacy:complete response rate": 1,
 "Efficacy:improvement in bone mineral density": 1,
 "Efficacy:response (SVR) to interferon monotherapy in HCV genotype 1 patients": 1,
 "Side Effect:end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance": 1,
 "Efficacy:response (SVR) in HCV genotype 1 patients": 1,
 "Efficacy:HAMD scores": 1,
 "Efficacy:improvement based on change of HAM-D score after antidepressant medication": 1,
 "Efficacy:trough metformin steady-state concentration": 1,
 "Disease:Dehydration": 1,
 "Side Effect:Dizziness, Side Effect:Drug Toxicity, Side Effect:Headache, Side Effect:Nausea, Side Effect:sedation": 1,
 "PK:Cmax and AUC of thiol metabolite": 1,
 "Side Effect:all and minor hemorrhage": 1,
 "Efficacy:PC20": 1,
 "Side Effect:adverse events, Side Effect:Cerebral Palsy, Side Effect:Hearing Loss": 1,
 "Side Effect:neuropathy": 1,
 "Efficacy:mean change in FEV": 1,
 "Efficacy:improvement in left ventricular(LV) remodeling and greater increase in LVEF (left ventricular ejection fraction)": 1,
 "PK:9-hydroxy-risperidone levels": 1,
 "PK:repaglinide plasma concentration (AUC) and Cmax": 1,
 "PK:active moiety levels": 1,
 "Efficacy:collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration": 1,
 "Side Effect:venoocclusive disease of the liver": 1,
 "Side Effect:graft vs host disease": 1,
 "Efficacy:tumor response": 1,
 "Efficacy:glucocorticoid responsiveness": 1,
 "Efficacy:Substance Withdrawal Syndrome": 1,
 "Side Effect:Neutropenia, Side Effect:Vomiting": 1,
 "Efficacy:improvement in left ventricular function (LVEF)": 1,
 "Efficacy:significantly greater improvement in left ventricular ejection fraction (LVEF)": 1,
 "Side Effect:gastrointestinal toxicity": 1,
 "Other:hydrochlorothiazide induced potassium excretion": 1,
 "Efficacy:bone mineral density response": 1,
 "PK:paroxetine serum concentration": 1,
 "Disease:Respiratory Tract Infections": 1,
 "Side Effect:triglyceride levels": 1,
 "PK:trough ( R , S )-methadone plasma concentrations": 1,
 "Side Effect:hemorrhagic cystitis": 1,
 "Efficacy:median survial time": 1,
 "Other:absolute leucocyte and neutrophil counts on day 15": 1,
 "Side Effect:Dyspepsia": 1,
 "Side Effect:Cryoglobulinemia": 1,
 "Efficacy:exacerbations": 1,
 "Efficacy:uncontrolled asthma": 1,
 "Side Effect:Infectious disease, Side Effect:Toxic liver disease": 1,
 "Side Effect:Infectious disease, Side Effect:Nephrotoxicity, Side Effect:Toxic liver disease": 1,
 "Disease:Cardiovascular Disease": 1,
 "Efficacy:rapid viral response (RVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients": 1,
 "Efficacy:immunological failure": 1,
 "Side Effect:Drug Toxicity, Side Effect:Gastrointestinal toxicity, Side Effect:Toxic liver disease": 1,
 "Other:primary outcome": 1,
 "Efficacy:median survival time (MST)": 1,
 "Efficacy:primary outcome": 1,
 "Side Effect:dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg": 1,
 "Efficacy:abstinence": 1,
 "PK:Cmax and a lower mean AUC": 1,
 "Efficacy:time to tumor recurrence": 1,
 "Efficacy:virological response": 1,
 "Disease:Cocaine dependence, Disease:Heroin Dependence": 1,
 "Side Effect:methotrexate-induced nodulosis": 1,
 "Efficacy:sustained virological response (SVR) and changes in viral load after 4 weeks of treatment": 1,
 "Side Effect:severe neutropenia": 1,
 "Other:warfarin dose requirement": 1,
 "Efficacy:disease activity as assessed by the physician": 1,
 "Side Effect:a significantly higher odds of Musculoskeletal adverse events (MSAEs) in postmenopausal hormone receptor (HR)-positive breast cancer patients": 1,
 "Side Effect:decreased hemocrit levels": 1,
 "PK:desipramine/2-hydroxy-desipramine ratio": 1,
 "Side Effect:Diarrhea, Side Effect:Drug Toxicity": 1,
 "Efficacy:longer median progression-free survival time": 1,
 "Side Effect:onset of toxicity": 1,
 "Efficacy:remission after second treatment switch": 1,
 "Efficacy:improved second treatment switch response": 1,
 "Side Effect:Cardiac rhythm disease": 1,
 "Side Effect:nausea and vomiting": 1,
 "PK:etravirine clearance": 1,
 "Efficacy:reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner,": 1,
 "Side Effect:Depression, Side Effect:Gastritis, Side Effect:Hypersensitivity": 1,
 "Side Effect:plasma levels": 1,
 "Side Effect:ACEI-related cough": 1,
 "Efficacy:bone mineral density": 1,
 "Efficacy:higher mean baseline HCV RNA level and steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV infected patients": 1,
 "Disease:Brain Neoplasms": 1,
 "Efficacy:time to improve (based on mean reductions from baseline in HRSD)": 1,
 "Other:significantly higher tramadol consumption in Chinese gastric cancer patients recovering from gastrectomy": 1,
 "Disease:Carcinoma, Squamous Cell": 1,
 "Efficacy:complete remission": 1,
 "Side Effect:plasma insulin levels": 1,
 "Efficacy:physical and life well-being quality of life (QoL) scales": 1,
 "Efficacy:over-anticoagulation": 1,
 "Disease:Methamphetamine dependence, Disease:Psychotic Disorder, Disease:Substance-Related Disorders": 1,
 "Efficacy:Renal transplant failure": 1,
 "PK:trough levels": 1,
 "Side Effect:Angioedema, Side Effect:Cough": 1,
 "Efficacy:reduction in systolic blood pressure": 1,
 "Efficacy:complete pathologic response": 1,
 "Side Effect:micronucleated binucleated cells": 1,
 "Disease:Cardiac rhythm disease": 1,
 "Other:overall survival": 1,
 "Other:endogenous levels of EPO": 1,
 "Side Effect:Peptic Ulcer Disease": 1,
 "Side Effect:Anemia, Side Effect:Neutropenia, Side Effect:Gastrointestinal toxicity": 1,
 "Disease:Sudden Infant Death": 1,
 "Efficacy:the lack of aspirin effect": 1,
 "Side Effect:Psychomotor Agitation": 1,
 "Side Effect:grade 3 or 4 gastrointestinal toxicity": 1,
 "Efficacy:24-h excretion of chloride and potassium": 1,
 "Efficacy:increased risk of being nonresponders": 1,
 "Efficacy:Coronary Artery Disease": 1,
 "Efficacy:benefit": 1,
 "Efficacy:aspirin-depressed thrombin generation and prolonged bleeding time after aspirin": 1,
 "Side Effect:Shortened QT interval": 1,
 "Side Effect:adverse events, Side Effect:Hand-foot syndrome, Side Effect:Hypertension": 1,
 "Efficacy:platelet aggregation after stimuli with adenosine diphosphate, collagen, and epinephrine": 1,
 "Efficacy:higher fentanyl dose requirement to achieve adequate pain relief in Chinese women undergoing gynecologic surgery": 1,
 "Efficacy:higher responsiveness to opioids and required less analgesic drugs in laboring women": 1,
 "Efficacy:less pain control in Japanese patients undergoing painful orofacial cosmetic surgery": 1,
 "PK:dose-adjusted serum olanzapine N-oxide concentrations": 1,
 "PK:plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs.": 1,
 "Efficacy:slower analgesic onset in European Americans undergoing oral surgery": 1,
 "Efficacy:apolipoprotein A1 and C3": 1,
 "Other:baseline proinsulin levels after adjusting for insulin levels": 1,
 "Side Effect:heart palpitations": 1,
 "Other:smoking initiation": 1,
 "Side Effect:Aggression, Side Effect:Depression": 1,
 "Side Effect:QT interval": 1,
 "Other:Cardiac Arrest, Other:Respiratory Insufficiency": 1,
 "Efficacy:probability of antiepileptic drug response": 1,
 "Efficacy:relapse in the central nervous system": 1,
 "Other:sensitive to antilymphocyte serum": 1,
 "Other:sensitivity to aspirin": 1,
 "Other:smoking quantity": 1,
 "PK:antidepressant response": 1,
 "Efficacy:antidepressant response": 1,
 "Other:Hypoglycemia": 1,
 "PK:acute rejection": 1,
 "PK:blood concentrations": 1,
 "Disease:Hot Flashes": 1,
 "Side Effect:decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation": 1,
 "Efficacy:platelet inhibition by aspirin": 1,
 "Side Effect:Aspirin-Exacerbated Respiratory Disease": 1,
 "Side Effect:Leukopenia, Side Effect:Mucositis": 1,
 "Efficacy:fatal coronary disease or nonfatal myocardial infarction": 1,
 "Efficacy:treatment failure in Japanese patients with with chronic genotype 1 HCV infection": 1,
 "Efficacy:response (SVR rate) to HCV triple therapy (telaprevir (TVR), peg-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy)": 1,
 "Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome": 1,
 "Efficacy:improvement based on HAM-D score percentage reduction": 1,
 "Other:tubular vacuolar degeneration": 1,
 "PK:dose-adjusted trough levels": 1,
 "Disease:interstitial fibrosis": 1,
 "Efficacy:Platelet reactivity after 9month of treatment": 1,
 "Efficacy:8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR)": 1,
 "Side Effect:blood loss": 1,
 "Side Effect:Leukopenia, Side Effect:Thrombocytopenia": 1,
 "Efficacy:improved left ventricular ejection fraction": 1,
 "Efficacy:acute cellular rejection": 1,
 "Efficacy:reduction in psychotic symptoms": 1,
 "Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome": 1,
 "Efficacy:bone marrow density in the lumbar spine": 1,
 "Efficacy:inhibition of FXIII activation by aspirin": 1,
 "Efficacy:reduction in luminal diameter": 1,
 "Side Effect:drug-induced ventricular arrhythmia and QT prolongation": 1,
 "Efficacy:lower levels of transthyretin precuror": 1,
 "Side Effect:acetylsalicylic acid-intolerant chronic urticaria": 1,
 "Side Effect:sensitivity to aspirin": 1,
 "Efficacy:Complete Remission": 1,
 "Efficacy:3-year Event Free Survival": 1,
 "Disease:delayed graft function": 1,
 "Side Effect:Leukopenia, Side Effect:Drug Toxicity": 1,
 "Other:Death, Other:Recurrence": 1,
 "Side Effect:Angina Pectoris, Side Effect:Myocardial Infarction": 1,
 "Disease:Attention Deficit Disorder with Hyperactivity": 1,
 "PK:bioavailability (AUC, CL & AUC/CL ratio)": 1,
 "Side Effect:general side-effects": 1,
 "Efficacy:relapse free time": 1,
 "Side Effect:Angina Pectoris": 1,
 "Side Effect:Peripheral Nervous System Diseases, Side Effect:Treatment modification": 1,
 "PK:unbound oral clearance for S-warfarin": 1,
 "Side Effect:adverse effect burden": 1,
 "Other:higher stable dose levels": 1,
 "Efficacy:clopi-H4 concentrations after 300 or 900 mg clopidogrel loading dose": 1,
 "Other:adverse cardiovascular outcomes": 1,
 "Side Effect:major cardiovascular events": 1,
 "Other:peak plasma concentration of increased prolactin": 1,
 "Disease:Syncope": 1,
 "Disease:Orthostatic Hypotension": 1,
 "PK:concentration-to-dose ratios": 1,
 "Disease:Coronary Artery Disease, Disease:Myocardial Infarction": 1,
 "Efficacy:transplant rejection": 1,
 "Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease": 1,
 "PK:erythromycin metabolism": 1,
 "Disease:Neural Tube Defects": 1,
 "Efficacy:response rate after 10 weeks of pioglitazone treatment": 1,
 "Disease:Seizures, Febrile": 1,
 "Efficacy:social and clinical needs": 1,
 "Efficacy:response at 4 weeks after the initiation of treatment": 1,
 "Side Effect:lumbar bone loss": 1,
 "PK:area under the curve from baseline to the last measured concentration": 1,
 "Side Effect:musculoskeletal toxicity": 1,
 "Efficacy:Thrombotic disease, Efficacy:Sudden cardiac death, Efficacy:Myocardial Infarction": 1,
 "Efficacy:metabolism of tramadol and decreased response to tramadol": 1,
 "PK:mean serum concentrations of sertraline and N-desmethyl sertraline": 1,
 "PK:fluvoxamine plasma concentrations": 1,
 "PK:area under the time-plasma concentration curve (AUC(0-24))": 1,
 "PK:inhibition of metabolism": 1,
 "Efficacy:adverse cardiovascular events": 1,
 "Other:Alcohol abuse, Other:Opioid-Related Disorders": 1,
 "Side Effect:Alcohol abuse, Side Effect:Heroin Dependence, Side Effect:Methamphetamine dependence": 1,
 "Efficacy:percentage change in HDL-C levels": 1,
 "Side Effect:Colitis": 1,
 "Other:remaining on steroids at 1 year after transplantation": 1,
 "PK:oral clearance (CL) of atazanavir": 1,
 "Side Effect:low leukocyte counts": 1,
 "Efficacy:treatment duration": 1,
 "Efficacy:reduction in C-reactive protein (CRP)": 1,
 "Side Effect:any grade 3 adverse event": 1,
 "Side Effect:lung function": 1,
 "Efficacy:fibrin clot formation time": 1,
 "Side Effect:Dose reduction, Side Effect:Treatment interruption": 1,
 "Side Effect:Hypersensitivity Syndrome": 1,
 "Other:Hearing Loss, Sensorineural": 1,
 "Efficacy:being sensitive to caffeine": 1,
 "Side Effect:insomnia": 1,
 "Disease:Neurotoxicity Syndromes, Side Effect:Neutropenia": 1,
 "Other:coronary flow reserve": 1,
 "Other:adenosine-stimulated myocardial flow": 1,
 "Other:Premature Birth": 1,
 "PK:erythromycin breath test": 1,
 "PK:bioavailabilty": 1,
 "PK:plasma AUC": 1,
 "Efficacy:disease progression": 1,
 "Other:early relapse": 1,
 "Side Effect:Hand-foot syndrome, Side Effect:Drug Toxicity": 1,
 "Efficacy:naltrexone-induced blunting of alcohol stimulation and alcohol craving": 1,
 "Disease:Muscular Diseases, Disease:Myalgia": 1,
 "Side Effect:Myelosuppression, Side Effect:Drug Toxicity, Side Effect:adverse events": 1,
 "PK:plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy": 1,
 "Side Effect: cardiovascular events": 1,
 "Other:Physiological sexual disorder": 1,
 "Side Effect:Gastrointestinal toxicity, Side Effect:Neurotoxicity Syndromes": 1,
 "PK:distribution volume": 1,
 "Side Effect:withdrawal": 1,
 "Other:collagen-induced platelet aggregation": 1,
 "Side Effect:Albuminuria, Side Effect:Hypertension": 1,
 "Efficacy:recurrence of disease": 1,
 "Other:progression-free survival": 1,
 "Disease:Peptic Ulcer Hemorrhage": 1,
 "Other:nicotine dependence": 1,
 "Side Effect:serum potassium": 1,
 "Side Effect:Anemia, Side Effect:Thrombocytopenia": 1,
 "Side Effect:Exanthema, Side Effect:Mucositis": 1,
 "Side Effect:major adverse cardiovascular events (MACE) (more than one year) when receiving a loading dose of 300 mg": 1,
 "Other:Brain Ischemia, Other:Myocardial Infarction, Other:Peripheral Vascular Diseases": 1,
 "Other:Diabetic Retinopathy, Other:Chronic Kidney Failure": 1,
 "Efficacy:reduction in ambulatory blood pressure": 1,
 "PK:metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole, R-5-hydroxyomeprazole and S-5-hydroxyomeprazole": 1,
 "Side Effect:leukocytes and neutrophils": 1,
 "PK:metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole and R-5-hydroxyomeprazole": 1,
 "Efficacy:progression free survival (PFS) time": 1,
 "Other:adverse events": 1,
 "Side Effect:Diabetes Mellitus, Type 2": 1,
 "Side Effect:composite outcome of non-fatal MI, all cause death and stent thrombosis": 1,
 "Efficacy:chemoresistance": 1,
 "Efficacy:Depression": 1,
 "Efficacy:Anxiety Disorders": 1,
 "PK:metabolism": 1,
 "Efficacy:CNS relapse, Efficacy:hematologic relapse": 1,
 "PK: apparent terminal elimination half-life": 1,
 "Side Effect:Mucositis, Side Effect:Oral Ulcer": 1,
 "Efficacy:dose-adjusted tacrolimus blood concentration": 1,
 "PK:area under the visual analog scale-time curve during the induced state": 1,
 "PK:dose": 1,
 "Efficacy:prothrombin time (PT) at induction": 1,
 "Side Effect:Hemorrhage, Side Effect:over-anticoagulation": 1,
 "Other:intake": 1,
 "Other:HMGCRv_1 expression and an increase in the expression of the full-length transcript": 1,
 "Efficacy:primary graft failure": 1,
 "Efficacy:Bronchopulmonary dysplasia": 1,
 "Other:serum and red blood cell folate concentrations": 1,
 "Efficacy:baseline mean arterial blood pressure": 1,
 "Efficacy:platelet inhibition": 1,
 "Other:High Platelet Reactivity": 1,
 "Other:heavy consumption": 1,
 "Side Effect:cardiovascular toxicity and symptoms": 1,
 "Disease:Cystitis": 1,
 "Efficacy:recurrence of breast cancer": 1,
 "Side Effect:Neurotoxicity": 1,
 "PK:serum uric acid": 1,
 "Side Effect:Drug psychosis": 1,
 "Efficacy:improved response": 1,
 "PK:mean plasma drug concentrations": 1,
 "Other:number of cigarettes smoked per day": 1,
 "Disease:Therapy-related acute myeloid leukemia (t-AML)": 1,
 "Other:high on-aspirin residual platelet reactivity": 1,
 "Other:outcome time to stable dose": 1,
 "PK:oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia": 1,
 "Side Effect:Gastrointestinal toxicity, Side Effect:Leukopenia, Side Effect:Toxic liver disease": 1,
 "Efficacy:3 year event free survival": 1,
 "Disease:Acute cellular rejection": 1,
 "PK:efflux of rhodamine from CD56+ natural killer cells": 1,
 "Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome": 1,
 "PK:S-mirtazapine plasma levels in non-smokers at day 14 of treatment": 1,
 "PK:serum concentrations of S(+)-mirtazapine,  mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine": 1,
 "Efficacy: on-treatment ADP-induced platelet aggregation": 1,
 "Efficacy:on-treatment ADP-induced platelet aggregation": 1,
 "\"Side Effect:Carcinoma, Squamous Cell\", \"Side Effect:Hyperbilirubinemia\", \"Side Effect:Nausea\"": 1,
 "PK:risk of being underdosed": 1,
 "PK:dose-adjusted blood levels": 1,
 "PK:dose-adjusted trough concentration": 1,
 "Other:creatinine clearance": 1,
 "PK:age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias": 1,
 "Efficacy:recurrence-free survival": 1,
 "Other:suicidal ideation": 1,
 "PK:ratio of 1,3 DMU/theophylline": 1,
 "Side Effect:Hallucinations": 1,
 "Efficacy:less decrease in the platelet reactivity after 600 mg of clopidogrel": 1,
 "Efficacy:antiplatelet effect to a 300 mg clopidogrel loading-dose up to 24 h following intervention": 1,
 "Other:Disease Free Survival": 1,
 "PK:levels of clopidogrel active metabolite": 1,
 "PK:dose-adjusted tacrolimus blood concentrations": 1,
 "Efficacy:Elevated systolic blood pressure, Efficacy:Elevated diastolic blood pressure": 1,
 "Other:Nephrotoxicity": 1,
 "Other:functional MRI reactivity to smoking images": 1,
 "Side Effect:urinary potassium excretion": 1,
 "PK:metformin uptake in HEK-293 cells and reduction in protein expression levels": 1,
 "Side Effect:Hypertension, Side Effect:Hand-foot syndrome": 1,
 "Efficacy:SVR (sustained virological response)": 1,
 "PK:repaglinide AUC": 1,
 "Side Effect:haematopoietic toxicity": 1,
 "Side Effect:Hepatocellular Carcinoma": 1,
 "Disease:Hypoglycemia": 1,
 "Efficacy:disease control rate and lower overall survival rate": 1,
 "PK:clopidogrel active metabolite level": 1,
 "Efficacy:post-treatment ADP-stimulated platelet aggregation": 1,
 "Side Effect:Sialoadenitis": 1,
 "Efficacy:high-on clopidogrel platelet reactivity": 1,
 "Side Effect:neurological events": 1,
 "Side Effect:adverse cardiovascular outcomes": 1,
 "Efficacy:chance of positive response to paclitaxel": 1,
 "Side Effect:myelosuppression": 1,
 "Disease:Gastric pH": 1,
 "Disease:Chronic Kidney Failure": 1,
 "Side Effect:Malignant Hyperthermia": 1,
 "Efficacy:average daily dose during the first period of stability": 1,
 "Efficacy:change in forced expiratory volume in 1 s (FEV1)": 1,
 "Side Effect:grade 3 hypertension": 1,
 "PK:in vivo metabolism of (S)-warfarin but not (R)-warfarin": 1,
 "Efficacy:greater platelet inhibition 2 h after a 600-mg dose": 1,
 "Efficacy:platelet inhibition 7h after a clopidogrel 600-mg loading dose": 1,
 "Other:Elevated circulating creatine kinase concentration": 1,
 "Efficacy:difference in fasting plasma glucose (before and after drug treatment)": 1,
 "Disease:Nausea, Disease:Vomiting": 1,
 "Side Effect:drug-induced lupus erythematosus due to hydralazine": 1,
 "Disease:Hyperlipidemias": 1,
 "Disease:Lymphopenia": 1,
 "Other:lymph node metastasis": 1,
 "Disease:Urologic Neoplasms": 1,
 "Efficacy:reduced GP IIb/IIIa activation and lower platelet activation": 1,
 "PK:Vmax": 1,
 "Side Effect:Agitation": 1,
 "Efficacy:HDL-cholesterol": 1,
 "Side Effect:gastrointestinal bleeding": 1,
 "Side Effect:acute gastrointestinal bleeding": 1,
 "PK:mean peak concentration in plasma and area under the plasma concentration": 1,
 "Efficacy:survival rate": 1,
 "Efficacy:lymph node metastases": 1,
 "Efficacy:treatment failure": 1,
 "Efficacy:inadequate inhibition of platelet activity": 1,
 "Side Effect:Dyspnea": 1,
 "Efficacy:a 22% increase in therapeutic warfarin dose requirement after adjustment for clinical and genetic covariates in Hispanic-Americans": 1,
 "Side Effect:drug induced liver injury": 1,
 "Efficacy:a 34% increase in therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in Hispanic-Americans": 1,
 "Side Effect:extrapyramidal symptoms, Side Effect:Parkinsonian Disorder": 1,
 "Side Effect:body weight gain": 1,
 "Efficacy:mean peak INR during week 1 of warfarin therapy": 1,
 "Side Effect:heart rate": 1,
 "Side Effect:hepatocellular injury": 1,
 "Disease:Alcohol abuse, Disease:Substance-Related Disorders": 1,
 "Side Effect:increased pulse rate": 1,
 "Disease:Constipation": 1,
 "Other:worse overall survival outcome": 1,
 "Efficacy:subclinical intra-stent thrombus": 1,
 "Efficacy:serum osteocalcin": 1,
 "Disease:Hypertriglyceridemia, Side Effect:Weight gain": 1,
 "Disease:platelet aggregation": 1,
 "Side Effect:Elevated systolic blood pressure": 1,
 "Efficacy:end of treatment abstinence": 1,
 "Disease:Cystic fibrosis pulmonary exacerbation": 1,
 "Efficacy:suboptimal reperfusion (post-PCI TIMI flow <3)": 1,
 "Efficacy:anti-VEGF injections": 1,
 "Other:disease-free survival and overall survival": 1,
 "Other:percentage of days abstinent and lower number of drinks per drinking day": 1,
 "Efficacy:worse prognoses": 1,
 "Efficacy:overall survival probability": 1,
 "Side Effect:Tremor, Side Effect:Diarrhea": 1,
 "Side Effect:Asthenia, Side Effect:Diarrhea, Side Effect:Neutropenia": 1,
 "Efficacy:progression-free survival (PFS) (P=0.00004) and overall survival (OS) (P=0.034)": 1,
 "Disease:Mucositis": 1,
 "Side Effect:Exanthema, Side Effect:Drug Hypersensitivity": 1,
 "Side Effect:IQ": 1,
 "Other:serum LDL": 1,
 "Side Effect:Anemia, Side Effect:Nephrotoxicity": 1,
 "Side Effect:Endometrial Hyperplasia": 1,
 "Side Effect:clopidogrel resistance": 1,
 "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome": 1,
 "Side Effect:Discontinuation, Side Effect:statin-related myopathy": 1,
 "Other:platelet reactivity by P2Y12 reaction units": 1,
 "Side Effect:adverse drug events": 1,
 "Efficacy:blood pressure (BP) reduction": 1,
 "Side Effect:necessity to reduce irinotecan dosage": 1,
 "Other:serum total cholesterol": 1,
 "PK:pitavastatin plasma concentrations (AUC) and Cmax": 1,
 "PK:AUC (p=0.002) and Cmax (p=0.003)": 1,
 "Side Effect:arousal dysfunction": 1,
 "Side Effect:Anemia, Side Effect:Leukopenia": 1,
 "Efficacy:poor-response to clopidogrel": 1,
 "Side Effect:Leukopenia, Side Effect:Neutropenia, Side Effect:Mucositis": 1,
 "PK:higher plasma concentrations of O-desmethyltramadol": 1,
 "Side Effect:withdrawal effects": 1,
 "Other:cortical silent period duration": 1,
 "Side Effect:adverse drug event": 1,
 "Side Effect:diarrhea within 24 hours and Thrombocytopenia": 1,
 "Side Effect:time to discontinuation or dose reduction": 1,
 "Side Effect:infusion related reaction": 1,
 "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity": 1,
 "Side Effect:Drug Toxicity, Side Effect:Toxic liver disease": 1,
 "Side Effect:Urinary Retention, Side Effect:Constipation, Side Effect:Nausea, Side Effect:Vomiting, Side Effect:Abdominal Pain, Side Effect:Exanthema, Side Effect:Wheezing, Side Effect:adverse events": 1,
 "Side Effect:Neutropenia, Side Effect:Diarrhea, Side Effect:Drug Toxicity": 1,
 "Efficacy:Discontinuation, Efficacy:Treatment interruption": 1,
 "Other:Iron Overload": 1,
 "Efficacy:Hypertension": 1,
 "Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting": 1,
 "PK:a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin": 1,
 "Other:allelic imbalence": 1,
 "Efficacy:IC-50": 1,
 "Other:Status asthmaticus": 1,
 "Efficacy:rates of target lesion revascularization and major adverse cardiovascular events": 1,
 "Efficacy:to be classified as clopidogrel poor responders": 1,
 "Efficacy:clopidogrel poor response": 1,
 "Side Effect:treatment interruptions": 1,
 "Side Effect:speed of platelet recovery": 1,
 "Side Effect:red blood cell transfusions": 1,
 "Other:severe exacerbations with asthma": 1,
 "Side Effect:CNS adverse events": 1,
 "Side Effect:severe emesis": 1,
 "Side Effect:Drug Toxicity, Side Effect:Leukopenia, Side Effect:Mucositis": 1,
 "Side Effect:haematological toxicity": 1,
 "Efficacy:maximal platelet aggregation": 1,
 "Side Effect:stent thrombosis (ST) after 1 year": 1,
 "PK:blood concentration/dosage ratio": 1,
 "Side Effect:Elevated diastolic blood pressure, Side Effect:Elevated systolic blood pressure": 1,
 "Other:event-free survival, Other:Overall survival": 1,
 "Side Effect:elevated transaminases": 1,
 "Side Effect:toxicity-related treatment failure": 1,
 "Side Effect:Postoperative Nausea and Vomiting, Side Effect:Vomiting": 1,
 "Side Effect:Dry mouth, Side Effect:Mucositis": 1,
 "Side Effect:Stomatitis": 1,
 "Other:dependence": 1,
 "Efficacy:peak cortisol response": 1,
 "Side Effect:Leiomyoma, Side Effect:Liver Disorder, Side Effect:Ovarian Cysts": 1,
 "Efficacy:reduction in pain AUC": 1,
 "Other:metabolic ratio DEM/DOR": 1,
 "PK:median AUC, plasma half-life and steady-state plasma concentrations of paroxetine": 1,
 "PK:plasma predose concentration (Ctrough)": 1,
 "PK:glucuronidation metabolic ratios": 1,
 "PK:mean area under the plasma concentration-time curve (AUC) of desipramine": 1,
 "PK:mean peak plasma concentration of H4": 1,
 "Side Effect:change in Lumbar Bone Mineral Density": 1,
 "Efficacy:poor response at 8 week of treatment": 1,
 "Efficacy:poor response at 6 week of treatment": 1,
 "PK:midazolam metabolic ratios by 45%": 1,
 "PK:dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid-7-O-glucuronide": 1,
 "PK: area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid": 1,
 "Side Effect:Suicide": 1,
 "Other:drug dosage altered": 1,
 "Efficacy:greater reduction in homocysteine": 1,
 "PK:antidepressant serum levels": 1,
 "Efficacy:time-to-tumor recurrence": 1,
 "Other:major adverse cardiac events": 1,
 "Other:subclinical acute rejection": 1,
 "Side Effect:Dry mouth, Side Effect:Erectile Dysfunction, Side Effect:Hyperhidrosis, Side Effect:Insomnia, Side Effect:Urinary Retention": 1,
 "Side Effect:Drug Toxicity, Side Effect:Hematologic Disorder, Side Effect:Leukopenia, Side Effect:Thrombocytopenia": 1,
 "Side Effect:Cocaine dependence": 1,
 "PK:fluoxetine plasma concentration": 1,
 "Other:longer titration to achieve optimal benefit": 1,
 "PK:dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid": 1,
 "Efficacy:number of failed medication trails": 1
}